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Abstract

ROLE OF NEUTROPHILS IN ENHANCING VASCULAR REACTIVITY TO
ANGIOTENSIN II IN PREECLAMPSIA

By Nikita Mishra, MBBS
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Major Director: Dr. Scott W. Walsh
Professor, Departments of Obstetrics and Gynecology, Physiology and Biophysics

Women with preeclampsia have enhanced vascular reactivity to Angiotensin II
(Ang II) and extensive vascular infiltration of neutrophils. The primary mechanism to
enhance vessel reactivity is RhoA kinase that phosphorylates MYPT1 to inhibit myosin
light chain (MLC) phosphatase. Therefore, MLCs remain phosphorylated and increase
sensitivity to calcium. Neutrophils release reactive oxygen species (ROS), which can
activate this pathway, so we hypothesized that neutrophils would enhance vessel
reactivity to Ang II. Omental vessels from normal pregnant women were used to study
vascular reactivity. Ang II dose response (0.001-10µM) was significantly enhanced with
perfusion of neutrophils (<2000/mm3, activated with IL-8) or ROS. Addition of

xviii
superoxide dismutase (SOD)/Catalase to quench ROS or 3µM Y-27632, a specific RhoA
kinase inhibitor, blocked enhancement. Vascular smooth muscle expression of pMYPT1
and pMLC in cell culture was significantly increased by neutrophils or ROS. The
increase was prevented by Y-27632. RhoA kinase activity assay showed a 3-fold increase
in RhoA kinase activity in omental vessels treated with ROS. Similarly, ROS also
enhanced vessel reactivity to another vasoconstrictor, norepinephrine, via RhoA kinase.
In preeclamptic women, increased neutrophil infiltration is associated with increased
vascular expression and production of matrix metalloproteinase-1 (MMP-1). MMP-1
activates protease activated receptor-1 (PAR-1), which could cause endothelial
endothelin-1 release, so we considered a novel hypothesis that MMP-1 might cause
vasoconstriction and enhance vessel reactivity to Ang II via PAR-1. Omental vessels
perfused

with

activated

MMP-1

(0.025-25ng/ml)

showed

dose-dependent

vasoconstriction. Perfusion of activated MMP-1 (2.5ng/ml) significantly enhanced dose
response to angiotensin II. MMP-1 mediated vasoconstriction and enhanced vessel
reactivity to Ang II was abolished by co-perfusion of 10µM SCH-79797, a specific PAR1 blocker, and by 5µM BQ-123, a specific endothelin-1 type A receptor blocker. These
data are the first to show that activated neutrophils enhance vascular reactivity to Ang II
via ROS and the RhoA kinase pathway. They are also the first to show that MMP-1
induces vasoconstriction and enhances vessel reactivity to Ang II. Thus, vascular
neutrophil infiltration leading to ROS and MMP-1 generation could be an important
mechanism for hypertension in preeclampsia.

CHAPTER 1

GENERAL INTRODUCTION

A. Preeclampsia
Preeclampsia is a hypertensive disorder of pregnancy, which results in
considerable maternal and fetal morbidity and mortality. Sixteen percent of all pregnancy
related deaths in the US from 1991-1999 were the result of pregnancy related
hypertension1. The incidence of preeclampsia is 7.6% in nulliparous pregnancies and
3.3% of all nulliparous women experience severe disease2. Preeclampsia is a disorder
more common at both extremes of age and also in the first pregnancy. Diastolic blood
pressure above 95 mmHg significantly increases fetal death rate. African American
women are 3 times more likely to die from preeclampsia as compared to Caucasian
women3. In developing nations the perinatal mortality is more than six times higher in
infants of preeclamptic women as compared to infants of normal pregnant women4
(WHO defines perinatal mortality as death of the fetus between 22 weeks of gestation and
seventh day of life and includes fetal deaths during childbirth). Minimum defining
criteria for preeclampsia are BP >140/90 mm Hg after 20 weeks’ gestation in a
previously known normotensive woman along with proteinuria of 300 mg/day or more5.
Complications include HELLP (hemolysis, elevated liver enzyme levels, and a low
platelet count) syndrome, eclampsia characterized by seizures with or without cerebral
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hemorrhage and risk of maternal death. Currently, the only definitive treatment is
delivery of the fetus and removal of the placenta. Since preeclampsia is usually seen early
in pregnancy (< 34 weeks of gestation), delivery of the fetus results in a high incidence of
pre-term infants. Pre-term infants are often low birth weight babies with high rates of
mortality and morbidity.

Pathophysiology of Preeclampsia: Preeclampsia is a topic that has been vastly studied
and yet a lot remains to be determined. A number of theories have been proposed to
explain pathogenesis of preeclampsia and I will attempt to discuss the relevant literature
to date.

1. Endothelial Dysfunction: The role of endothelium in the pathogenesis of preeclampsia
is complex and involves a number of factors that ultimately lead to inappropriate
endothelial cell activation, also known as endothelial cell dysfunction6. Endothelial
activation results in increased production of vasoconstrictors and pro-coagulants like Von
Willebrand’s factor (vWF)7, endothelin-1 (ET-1)8, thromboxane, prostaglandin-F2α
(PGF2α)9 and platelet derived growth factor (PDGF) along with a decrease in production
of vasodilators10 and anti-coagulants like prostacyclins11,

12

, nitric oxide (NO)13 and

endothelium derived hyperpolarizing factor. This imbalance results in a vasoconstricted
state that causes hypertension and reduced capacity of the vascular system in
preeclampsia. The mitogenic activity of PDGF results in vessel hyperplasia and
thickening14, akin to atherosclerosis. Moreover, placental factors in preeclampsia disrupt
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endothelial junction molecules and increase endothelial permeability , which can explain
15

the edema and proteinuria in preeclampsia16. Endothelial activation also releases
chymase, interleukin-8 (IL-8) and P-selectin and up-regulates expression of vascular cell
adhesion molecule-1 (VCAM-1)17. IL-8 is a potent chemo-attractant for neutrophils,
while VCAM-1 and P-selectin18 promote attachment and infiltration of immune cells
across the endothelium, thus promoting neutrophil infiltration and vascular inflammation
in preeclampsia. Endothelial release of chymase increases local levels of angiotensin II
(Ang II) by catalyzing conversion of Angiotensin I to Ang II19.

2. Oxidative stress: Oxidative stress is a state characterized by an excess of oxidants as
compared to anti-oxidants. The major oxidants are free radicals and reactive oxygen
species (ROS). Free radical is defined as a molecule containing one or more unpaired
electrons and capable of independent existence. ROS is a collective term for oxygen
derived free radicals as well as non-radical derivatives of oxygen such as hydrogen
peroxide (H2O2)20. Antioxidants are compounds that can react with ROS and free radicals
to convert them into non-oxidizing molecules. Major cellular antioxidant enzymes are
catalase, glutathione peroxidase and superoxide dismutase (SOD). SOD dismutates the
superoxide anion (O2-) to H2O2 and oxygen21. Activity of SOD is significantly decreased
in preeclampsia22, 23. Catalase and glutathione peroxidase catalyse the conversion of H2O2
to water and oxygen21. Other known antioxidants are Vitamins A, E and C, as well as uric
acid, transferrin, ceruloplasmin and quinines. In preeclampsia, there is a reduction in the
total antioxidant capacity of the serum24 along with an increase in superoxide production.

4
In preeclampsia, levels of nitric oxide (NO) metabolites and endothelial nitric oxide
synthase (eNOS) are elevated25. Although this would seem to be protective as NO is a
vasodilator, overproduction of O2- by neutrophils26 results in endothelial cell injury
because endothelial NO reacts with O2- to form peroxynitrite (ONOO-)27. Peroxynitrite
levels are elevated in preeclampsia28 and can induce eNOS uncoupling which causes the
NO synthesizing enzyme to produce superoxide29. Peroxynitrite thus interferes with NO
dependent relaxation and can also decompose into the hydroxyl ion (OH-)20. Hydroxyl
ion is a potent oxidizing agent that can directly impair cellular function and mediate the
vascular response in preeclampsia20. Levels of 8-epi-PGF2α, a marker of lipid
peroxidation, are increased in preeclamptic women30. Also abnormal mitochondria in
preeclamptic placentas31 are indicative of oxidative stress at the cellular level32,

33

.

Oxidative stress and lipid peroxidation of the endothelial cell membrane alter its fluidity
and result in an increase in endothelial cell junction permeability34.

3. Thromboxane/Prostacyclin Imbalance: In 1985, Walsh first demonstrated the presence
of thromboxane/prostacyclin imbalance35. Within the placenta, lipid peroxides are formed
from the interaction of polyunsaturated fatty acids with free radicals in normal
pregnancy36. In placentas from preeclamptic pregnancies there is significantly more lipid
peroxide formation37,

38

. Lipid peroxides are known to stimulate cyclooxygenase

production of prostaglandins and thromboxanes39. Lipid peroxides also inhibit the
prostacyclin synthase enzyme40,

41

. Further evidence comes from studies showing

decreased plasma concentrations and urinary excretion of prostacyclin (PGI2) metabolites
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by preeclamptic women . Thus, enhanced lipid peroxide formation in preeclamptic
11

placental tissue results in thromboxane/prostacyclin imbalance favoring thromboxane42.
Thromboxane A2 is a potent vasoconstrictor43 while PGI2 is a potent vasodilator and
inhibitor of platelet aggregation43,

44

. Thus, the thromboxane/prostacyclin imbalance

induces placental as well as systemic vasoconstriction and can explain the placental
hypoperfusion and intra-uterine growth restriction seen in preeclampsia.

4. Vasomotor tone and reduced blood supply: Lipid peroxides have been shown to cause
vasoconstriction in the systemic vasculature45 and could explain maternal hypertension in
preeclampsia. Lipid peroxides also increase calcium influx within the cells45. The
thromboxane/prostacyclin imbalance and increased sensitivity to usual pressors46 in
preeclampsia could also partially explain the maternal hypertension and rise in basal tone.
In preeclampsia, plasma volume is reduced, however levels of atrial natriuretic peptide
(ANP) are elevated47 and plasma renin activity is low48. This suggests that the vasculature
is overfull even though there is low circulating plasma volume49 and that there is an even
greater reduction in the capacity of the vasculature than the reduction of plasma volume.
This is explained by the combined result of vasoconstriction and the formation of
microthrombi in the vasculature secondary to the pro-coagulant state in preeclampsia.
The end result is hypertension and reduced blood supply to all organs.

5. Abnormal placentation: Evidence for a role of abnormal placentation in the
pathogenesis of preeclampsia is evident from a case report describing a woman with an
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abdominal pregnancy and retained placenta. She remained preeclamptic for many months
until the placenta was absorbed50. Thus the presence of a placenta is a prerequisite to the
development of preeclampsia but obviously not sufficient cause of preeclampsia in itself.
It has been suggested that the underlying cause of preeclampsia is reduced placental
perfusion. During normal pregnancy, the spiral arterioles of the non-pregnant state
undergo considerable vascular remodeling to supply the inter-villous space of the
developing placenta. These small muscular arteries increase considerably in diameter and
lose their muscle and inner elastic lamina51. During the first ten weeks of gestation high
metabolic requirements of the fetus result in a hypoxic stimulus within the placenta
which leads to the release of vascular endothelial growth factor (VEGF) from decidual
macrophages. VEGF is an angiogenic factor that acts on the VEGF receptors on
cytotrophoblasts and transforms them into endothelial-like cells. The lumen and vessel
walls of the spiral arteries are invaded by extracellular trophoblast. This trophoblast
invasion extends into the inner third of the myometrium and is completed by 20 weeks of
gestation52. These changes do not proceed in a normal manner in preeclamptic
pregnancies. In preeclampsia, these changes may be absent or restricted to only the
superficial decidual segment of the spiral arteries51. This leads to decreased placental
perfusion in preeclampsia.

B. Neutrophils in Preeclampsia:
Neutrophils are the most abundant white blood cells (WBC) in the circulation
(65% of all WBC). They are the first line of defense against bacterial and fungal
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infections to be recruited to sites of infection and they contain an impressive armory of
cytotoxic mechanisms capable of killing a wide range of microbial organisms.
Inappropriate activation of these cytotoxic mechanisms can lead to tissue damage.
Therefore, the process of neutrophil emigration and activation is controlled at several
stages53. In preeclampsia all these controls are overcome to result in neutrophil
infiltration and activation in the absence of any underlying infection.
Neutrophil numbers are increased up to 2.5 fold in normal pregnancy65. Luries et
al reported further increase neutrophil numbers in preeclampsia as compared to normal
pregnancy54. Greer et al were the first to present evidence for neutrophil activation in
preeclampsia by the demonstration of elevated levels of neutrophil elastase, a marker of
neutrophil activation, in plasma from preeclamptic women as compared to that from
normal pregnant women55. Increased neutrophil elastase levels in preeclamptic women
are independent of the absolute neutrophil count 56 which is the number of neutrophils per
mm3 of whole blood. The substrates for neutrophil elastase are elastin, collagen,
fibrinogen and proteoglycans56. Thus, along with other proteases it can cause vascular
basement membrane damage and facilitate tissue infiltration of neutrophils. Vascular
basement membrane damage could also contribute to the edema and proteinuria of
preeclampsia.
Neutrophil activation in preeclampsia is confined to the maternal circulation57.
Additional evidence of neutrophil activation in preeclampsia came with demonstration of
increased neutrophil expression of CD11b; a surface marker of neutrophil activation58.
Also, neutrophils from preeclamptic women generated significantly increased levels of

ROS and reduced expression of L-selectin (CD62L)

59, 60
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. Recently, it was shown that

neutrophils isolated from preeclamptic women generated significantly more superoxide
than the neutrophils from normal pregnant women but did not differ significantly from
neutrophils of non-pregnant women61. Also, the exposure to plasma from normal
pregnant women inhibited superoxide production by non-pregnant neutrophils but did not
affect superoxide production by preeclamptic neutrophils61, suggesting altered response
of preeclamptic neutrophils to the protective anti-oxidant factors in plasma from normal
pregnant women.
Neutrophil gelatinase associated lipocalin (NGAL), a matrix glycoprotein of
human neutrophil granules62, is strongly induced during neutrophil activation and
inflammation63. Elevated levels of NGAL have been reported in women predestined to
develop preeclampsia. NGAL levels showed a strong positive correlation with
development of hypertension and proteinuria64; providing additional evidence to support
the role of neutrophils in the pathogenesis of preeclampsia. Luppi et al reported 4.5-fold
increase in the DNA binding activity of NF-κB in preeclamptic women as compared to
normal pregnant women not in labor60. Even when compared to normal women in labor,
there was a 3.5 and 2 fold increase in the nuclear translocation of NF-κB p50 and p65
subunits, respectively. Nuclear translocation of NF-κB subunits initiates transcription of
genes involved in regulation of inflammation65

Source of activation of neutrophils:

9
i)

Placenta

Neutrophil activation by placental lipid peroxides was first suggested by Walsh in
199436. The primary source of lipid peroxides in the placenta is the trophoblast layer of
cells that bathe the maternal blood38. Thus the neutrophils circulating within the
intervillous space are exposed to high levels of lipid peroxides

36

(Fig 1). Lipid

peroxidation of leukocytes results in sustained activation66. Lipid peroxide production is
significantly higher in placentas of preeclamptic women38. Placenta is also a rich source
of linoleic acid67, which is known to stimulate placental release of thromboxane.
Thromboxane in turn stimulates TNFα and superoxide production by neutrophils68.
Placental secretion of TNFα can also directly activate neutrophils circulating within the
intervillous space. Placental mRNA expression and synthesis of TNFα is significantly
higher in preeclamptic placentas69. Increased placental production and circulation of
synctiotrophoblast microvillus membrane micro-particles (STMB), known to activate
neutrophils via increased expression of CD11b and superoxide production, has been
reported in preeclampsia70.
Brinkmann et al reported that neutrophil activation by IL-8, LPS or phorbol
myristate acetate resulted in the release of granule proteins and chromatin which formed a
web of extracellular fibril matrix called neutrophil extracellular traps (NET)71. NET is
composed of a chromatin DNA backbone with histones, granular peptides and enzymes
like elastase and myeloperoxidase71, 72. Recently it was reported that placentally derived
STMB and soluble factors like IL-8 efficiently activate neutrophils to generate NET’s
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rich in DNA, elastase and histones, which trap STMB particles . Preeclamptic placentae
73

showed significantly increased numbers of NET’s within the intervillous space73. NET’s
are also released within the maternal circulation and may explain the increased
concentrations of maternal cell free DNA in preeclamptic women reported by Zhong74.
They also cause physical obstruction to blood flow within the placenta and contribute to
placental hypo-perfusion and IUGR.

ii)

Cytokines and cell adhesion molecules

Neutrophils are also activated by TNFα. Increased levels of circulating VCAM-1
and intercellular cell adhesion molecule-1 (ICAM-1)75-77 lead to increased neutrophil
adherence to the endothelium78. TNFα enhances neutrophil superoxide production79 and
levels of TNFα and its soluble receptor are elevated in plasma and amniotic fluid of
preeclamptic women80,

81

. Elevated levels of IL-6 in preeclampsia60,

80, 82

are also

associated with increased circulating ICAM-1 and increased endothelial expression of
VCAM and E-selectin83. Increased VCAM, E-selectin and ICAM-1 facilitate neutrophil
adherence to the endothelium84, 85. IL-186 and IL-8 are potent activators of neutrophils87
while IL-6 and ET-1 prime neutrophils for superoxide production88.

iii)

Small dense LDL and VLDL

11
In preeclampsia concentrations of small dense LDL and VLDL-1 are increased.
Small dense LDL is readily oxidized. Oxidized LDL induces VCAM-1 expression on
endothelial cells89 and CD11b/CD18 expression on neutrophils promoting neutrophil
adhesion to the endothelium90.

iv)

ET-1

Levels of ET-1 are increased in preeclampsia. ET-1 is involved in neutrophil
superoxide production91, intracellular calcium release92 and neutrophil aggregation93 and
adhesion94.

Activated neutrophils in turn release TNFα, IL-6 and superoxide, which can then
generate feed forward cycles of neutrophil activation.

Evidence of neutrophil infiltration of systemic vasculature in preeclampsia:
Immunohistochemistry has shown the presence of significantly increased numbers
of neutrophils flattened onto the endothelium, infiltrating within the intima and within
muscular layers of resistance size arteries of the systemic circulation in preeclamptic
women as compared to that in the vasculature of normal pregnant women95, 96. Using the
CD66b marker for granulocytes (96% of granulocytes are neutrophils), it has been shown
that there is significantly greater neutrophil infiltration within the systemic vasculature in
preeclamptic women as compared to normal pregnant women96,

97

. Furthermore,
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activation of the neutrophils infiltrating the vasculature was demonstrated with markers
for activated NF-κB, COX-2 expression95, IL-8 and ICAM-196. Of these, IL-8 is a potent
chemo-attractant for neutrophils. Increased expression of IL-8 in the VSMC’s establishes
a concentration gradient of IL-8 across the endothelium, promoting neutrophil emigration
across the endothelium96. Increased endothelial ICAM-1 expression promotes neutrophil
adhesion and activation85. Neutrophil activation and release of ROS along with cytokines
like TNFα and IL-1 can induce NF-κB activity and trigger a cascade of inflammatory
reactions65. NF-κB activation triggers up-regulation of genes encoding pro-inflammatory
cytokines, adhesion molecules, chemokines and enzymes like COX-298 causing
inflammation.
In the presence of inflammation, endothelial cells express antigens that recruit,
sequester and transfer circulating cells to the site of inflammation. This is a crucial and
necessary role of endothelial cells to effect the neutrophil emigration. In preeclampsia,
there is increased expression and circulating concentrations of VCAM-1, ICAM-199 and
P-selectin100. Endothelial activation by placental derived factors results in up-regulation
of adhesion molecules, such as P-selectin and E-selectin101. Both are involved in the early
phases (capture and rolling) of neutrophil/endothelial and platelet/endothelial interaction
and adhesion. The increased ICAM-1 expression on endothelial cells along with
increased CD11b and IL-8 receptor expression on neutrophils promotes neutrophil
emigration in preeclampsia.
In preeclampsia inappropriate endothelial activation or endothelial dysfunction
results in translocation of vWF and fibronectin from the abluminal surface to the luminal
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surface of endothelial cells. vWF and fibronectin are both pro-coagulant molecules with
adhesive properties and when on the luminal surface they interact with platelets and
leukocytes in the circulation to promote neutrophil emigration102.
Neutrophil degranulation on endothelial cells results in degradation of fibronectin
and spread of fibronectin fragments on endothelial cells. Degraded fibronectin stimulates
the neutrophils and can induce further fibronectin breakdown setting up a feed forward
inflammatory loop. Loss of the fibrillary architecture of fibronectin on endothelial cells is
a marker of endothelial injury103.
preeclampsia104

suggesting

Circulating levels of fibronectin are elevated in

increased

neutrophil

degranulation

and

fibronectin

degradation in preeclampsia. Neutrophil degranulation at the endothelial surface leads to
endothelial damage and dysfunction.

Neutrophils and oxidative stress:
Neutrophil activation and degranulation is capable of generating considerable
oxidative stress as activated neutrophils make large quantities of superoxide via the
NADPH oxidase enzyme system105. Also, 1-4% of oxygen used in the mitochondrial
electron transport pathway is converted to superoxide106. Wright et al first provided direct
evidence of nitric oxide generation by human neutrophils. In neutrophils, nitric oxide is
produced by oxidation of one of the terminal nitrogens of arginine via calcium-dependent
inducible nitric oxide synthase (iNOS-Type II)107,

108

. The interactions and effects of

neutrophil generation of reactive oxygen species and reactive nitrogen intermediates
relevant to preeclampsia are illustrated in Fig 2. Hydrogen peroxide (H2O2) can easily

109

pass across cell membranes
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. However, within the neutrophils in the presence of

myeloperoxidase, which is abundant in primary azurophilic granules of neutrophils110, 111,
H2O2 primarily reacts with halides like Cl- to form hypochlorous acid (HOCl). HOCl is
known to inactivate sulfhydryl dependent transporter systems within cell membranes112.
Peroxynitrite is a potent and reactive oxidant113

that can damage endothelial cells

directly114, 115 and impair vascular permeability116. In the presence of H2O2, the half life
of ONOO- is prolonged117. Transition metals catalyze formation of hydroxyl ion (OH-)
and nitronium ion (NO2+) from ONOO-. Hydroxyl ion is a highly reactive oxidant that
can directly impair cellular function20.

NET’s generate oxidative stress in the placenta by interfering with blood flow
through intervillous space increasing the degree of hypoxia73. Hypoxia promotes
placental release of inflammatory cytokines like IL-6 and IL-8. These cytokines are
known to stimulate NET production by neutrophils118 resulting in a vicious cycle. Thus,
neutrophils play a role in the pathogenesis of preeclampsia by promoting placental
hypoxia, systemic endothelial dysfunction and generation of local oxidative stress in the
vasculature.

C. Enhanced Vascular Reactivity to Ang II in Preeclampsia:
Women with preeclampsia have hypertension by definition. Though normal
human pregnancy is characterized by increased levels of circulating angiotensin II119,
normal pregnant women are relatively resistant to the effects of infused angiotensin II 120.
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In contrast, the vasculature of preeclamptic women is highly sensitive to the
vasoconstrictive effect of angiotensin II and also other vasopressors46,

121, 122

. In a

prospective clinical study of primigravid women (women who are pregnant for the first
time), Norman Gant and colleagues demonstrated enhanced vascular responsiveness to
Angiotensin II (Ang II) in women who go on to develop preeclampsia123. Primigravid
women who went on to develop pregnancy-induced hypertension required a lower dose
of Ang II infusion in order to elicit a pressor response of > 20 mmHg diastolic pressure as
compared to those who remained normotensive throughout pregnancy. Results of the
study are depicted graphically in Figure 3. This classic paper established that increased
sensitivity to Ang II induced pressor response preceded the development of
preeclampsia123. Most studies following this work reported that neither renin, renin
substrate nor Ang II were elevated in preeclamptic women48,

124

supporting a role of

enhanced vascular reactivity to Ang II in preeclampsia. In this section I will briefly
review the regulation and mechanism of action of Ang II and go on to explain how
neutrophil release of ROS could enhance the vasoconstrictive action of Ang II via
activation of the RhoA kinase pathway.

i. Angiotensin II and VSMC Contraction:

a. Angiotensin II (Ang II) Generation

i.
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ACE pathway: Renal renin catalyses the conversion of angiotensinogen to
angiotensin I (Ang I). Angiotensin converting enzyme (ACE) within the lung
vasculature catalyses the release of histidyl-leucine from the COOH-terminus of Ang
I to yield the octapeptide vasopressor, Ang II125.

ii.

Another mechanism of Ang II generation resides within the heart and systemic
vasculature, the chymase/non-ACE pathway: Chymase or chymotrypsin like serine
protease (CLP) was first found in mast cells126. Subsequently, it was shown to be
present within the heart 19and isolated human arteries127. Eighty percent of the Ang II
in the human heart comes from chymase dependent conversion of Ang I to Ang II19.

b. Mechanism of Action:
The vascular effects of Ang II are predominantly mediated by the AT1 receptor
(Fig.4). The downstream cell-signaling molecules involved are phospholipase C, rise in
intracellular calcium levels, protein kinase C (PKC)128, tyrosine kinases129, mitogenesis
associated protein kinase (MAPK) and the janus kinase (JAK) pathways. Tyrosine kinase
and MAPK modulate contraction in smooth muscle through a variety of mechanisms129.

i)

VSMC contraction: Myosin light chain kinase (MLCK) is a Ca-calmodulin

dependent enzyme that phosphorylates the regulatory myosin light chain (MLC)
permitting its activation by actin130. Cross-bridge cycling of phosphorylated MLC and
actin results in VSMC contraction. Agonists like Ang II and ET-1 activate Ca++ influx

++

through ligand-gated and store operated Ca

131

channels in VSMC
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. However, the work

of Fujihara suggests that agonist induced tonic contraction is largely a result of Ca++
sensitizing effect of activated RhoA/Rho kinase pathway132 with a possible small
contribution of Ca++ influx that maintains [Ca++]i above basal levels. Ang II induced
VSMC contraction and hypertrophy is mediated via AT1-R [G-Protein coupled receptor
(GPCR)] activation of Rho/RhoA kinase and protein kinase C (PKC) pathway133.

ii)

Calcium sensitization pathways: The RhoA/Rho kinase pathway is a major

mechanism of Ca++ sensitization that acts by inhibition of smooth muscle myosin
phosphatase (Fig 4)134. In VSMCs, several agonists including Ang II stimulate Rho
kinase activity by increasing GTP-bound Rho A150. Rho activation also up-regulates
AT1-R mRNA expression, thus enhancing Ang II effects via receptor up-regulation135.
Activated RhoA kinase phosphorylates the regulatory subunit of MLC phosphatase,
MYPT1. This inhibits MLC phosphatase and slows de-phosphorylation of MLC134, 136,
137

. Increased levels of pMLC lead to Ca++ sensitization. Ang II induced Rho/RhoA

kinase activation requires a tyrosine kinase, PYK-2, and its upstream activator, PKC-δ.
PYK-2 may signal to Rho via phosphorylation and activation of Rho GEF138. Y-27632, a
selective RhoA kinase inhibitor139, can induce Ca++- desensitization by inhibiting Ang II
induced MYPT1 phosphorylation at threonine 696133.
Evidence for a role of PKC in Ca++ sensitization of the contractile apparatus of
VSMC’s comes from sustained VSMC contraction by direct activation of PKC by
phorbol esters without significant changes in [Ca++]i140,

141

. PKC activation results in
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activation of CPI-17, a phosphatase-1 inhibitor, which inhibits MLC phosphatase leading
to Ca++ sensitization142,

143

. ET-1 increases PKC activity in VSMC144and thereby

increases vascular reactivity to Ang II.
Calcium desensitization is mediated by NO and cyclic guanosine monophosphate
(cGMP)

145, 146

. cGMP mediated protein kinase (PKG) antagonizes RhoA/Rho kinase

pathway by reversal of G-protein coupled inhibition of MLC phosphatase by PKG
activation147, 148. Cyclic AMP and cGMP activate A-kinase & G-kinase149 respectively,
which phosphorylate site A of MLCK, decreasing its affinity for Ca-calmodulin 10fold150. In this way NO and cGMP reduce MLCK activity leading to Ca++ desensitization.

iii)

Sympathetic Nervous System: In vivo, vascular smooth muscle is under the

influence of the sympathetic system. Ang II inhibits K+ currents in neurons leading to
increased Ca++ current and increased neuronal firing leading to norepinephrine (NE)
release and activation of the sympathetic system151. Although sympathetic activity is
decreased during normal pregnancy it is reversibly increased in stress and in women with
preeclampsia152. Stress related sympathetic stimulation and NE release might have a
contributory role in the development of preeclampsia153-155. Treatment of cultured
sympathetic cells with preeclamptic plasma results in significant increase in NE
release156. NE is the most important neurotransmitter of the sympathetic system. In
subcutaneous

resistance

sensitization157,

158

arteries

of

preeclamptic

women,

NE

induced

Ca++

, which was previously shown to be associated with an increase in

pMLC as a result of decreased MLC phosphatase activity mediated via PKC159. However,
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as opposed to Ang II induced hypertension, NE induced hypertension did not increase
superoxide production or oxidase expression160.

ii. Sources of Ang II in Preeclampsia:
During pregnancy, apart from the renal renin angiotensin aldosterone system
(RAAS), there is also the placental RAAS

161

. Placental hypoxia in preeclampsia can

induce increased ACE mRNA expression and activity in the venous endothelial cells of
the stem villous which is the main site of conversion of Ang I to Ang II in the placenta162.
The levels of ACE and Ang II are increased in placental tissues and umbilical venous
plasma of preeclamptic women163. Shah introduced the concept that due to reduced
perfusion of the utero-placental unit in preeclampsia, the placenta behaves like the
clipped kidney of the 2 kidney 1 clip Goldblatt model164. In concurrence with the
implication of placental RAAS activation (akin to the clipped kidney) in preeclampsia,
renin gene expression and Ang II levels were 3-fold higher in the decidua and chorionic
villi of preeclamptic women165. Preeclampsia is characterized by up-regulation of AT1R
in the decidua166, however, the aminopeptidase-A (AP-A) enzyme cleaves N-terminal
aspartyl acid residue of Ang II to form its inactive metabolite Ang III167 so the enzyme
acts as a feto-maternal barrier to transport of Ang II across the placenta168. AP- A is
induced by Ang II via AT1 and AT-2 receptors. The AP-A system is ideally localized
within the basal zone of the synctiotrophoblast to effectively remove Ang II from the
fetal circulation (up to 90%)169.
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Apart from placental Ang II, endothelial cells can be a source of local release of Ang II
on VSMCs. Earlier studies have shown renin substrate, renin activity, Ang I and Ang II
generation within endothelial cells170, 171. Increased CLP and chymase activity is seen in
women with preeclampsia172,

173

. Thus, CLP/chymase dependent generation of Ang II

and/or ET-1 may regulate contractile function of the VSMC in preeclampsia. Also,
increased basal release of angiotensin II and endothelial CLP/chymase activation was
reported in response to stimulation by preeclampsia placental conditioned medium (PECM)172. Basal release of Ang II increased in a concentration dependent manner with
application of apical chymotrypsin was inhibited by chymotrypsin inhibitor and
unaffected by ACE-I. This suggests additional angiotensin II generation by the
endothelial cells via the chymase/non-ACE pathway right onto the vascular smooth
muscle cells of the vessel walls in preeclamptic women. In preeclampsia high levels of
Ang II locally can induce phosphodiesterase 1A1 (PDE1A1) which degrades cGMP to
5’-GMP174. Inactivation of cGMP by AngII may also play a role in the development of
Ca++- sensitization in VSMCs. PE-CM also induced translocation of the AT-1 receptor
from the cytosol to the nuclei which suggests AT-1 receptor up-regulation by the PECM172 potentially leading to increased sensitivity to Ang II.

iii. Role of Angiotensin II in preeclampsia:
Angiotensin II contributes to ROS production and inflammatory responses via
activation of NADPH oxidase and NF-κB in trophoblasts and VSMCs175, 176. This effect
is important physiologically as even a low dose of Ang II (10-10M) has been shown to

177, 178

increase NADPH oxidase derived ROS in cultured VSMCs
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. Baseline ROS

production by vascular NADPH oxidase is low. On stimulation, ROS production by
vascular NADPH oxidase is only a third of what neutrophils produce, but it is sustained
for a longer duration179. Long term (hours to days) ROS generation is mediated by
p22phox gene up-regulation180 while short term ROS production probably involves
assembly of component subunits into a functional oxidase and/or subunit biochemical
modifications181. Increased amount of superoxide produced in VSMCs combines with
NO to form ONOO-182. Peroxynitrite contributes to vasoconstriction and vascular
injury183. Increase in NO degradation rather than reduced production impairs endothelium
dependent vasodilation184. Angiotensin II stimulated ROS production within the VSMC
induces degradation of I-κB leading to NF-κB activation185, 186. Ang II and AT1-AA also
stimulate endothelial cell expression of tissue factor (TF)187. Enhanced TF activity in
preeclampsia is associated with enhanced cell adhesion and migration of immune cells188
promoting neutrophil adhesion, emigration and synthesis of TNF-α and IL-6189.
Angiotensin II also promotes expression of soluble fms-like tyrosine kinase (sFlt-1) in
decidual tissue, sFlt-1 is an antagonist of VEGF and placental growth factor190 believed
to play a role in the pathogenesis of preeclampsia by interference with placentation and
vascular remodeling.

D. Role of neutrophils in enhanced vascular reactivity to Ang II in preeclampsia
There are a number of ways neutrophils could cause vasoconstriction or enhance
vascular reactivity to Ang II. Direct vasoconstrictive effects of thromboxane A2 released
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191

by activated neutrophils infiltrating the systemic vasculature of preeclamptic women

could contribute to hypertension in preeclampsia in addition to ROS generation by
neutrophils which impairs stability of the endothelium derived vascular relaxing factor,
NO192. Neutrophil production of hydroxyl radicals, superoxide anions and iron dependent
reactive species can impair endothelium dependent relaxation193. High concentrations of
ROS inhibit the PI3K/Akt pathway decreasing endothelial NO production and thus
increasing vascular tone194, 195. ROS are known to activate the Rho kinase pathway in a
rat model of Ang II induced hypertension196. Neutrophil release of ROS acting via the
Rho kinase pathway could increase [Ca++]i sensitivity to Ang II. ROS can also stimulate
release of ET-1197. ET-1 is a vasoconstrictor that also enhances [Ca++]i sensitivity in
VSMC’s198. Relaxin is a hormone which when incubated with human neutrophils causes
a reduction in CD11b expression, superoxide generation, [Ca++]i, release of granules and
chemotactic migration199. Relaxin is a potent vasodilator and its levels decline with
advancing gestation. In preeclampsia, low levels of relaxin are associated with
vasoconstriction200 and possibly neutrophil activation secondary to loss of the regulatory
control of relaxin.
Neutrophil release of pro-inflammatory cytokines like IL-6 and TNF-α can
activate the sympathetic nervous system201. Three-fold higher sympathetic nerve activity
is seen in preeclamptic women as compared to normotensive pregnant women202. IL-6
treated rats have higher plasma renin activity, enhanced vasoconstriction, decreased
pressure natriuresis and they develop hypertension203. TNF-α infusion causes
hypertension associated with transcriptional up-regulation of the ET-1 gene in the kidney,
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204

placenta and vasculature

. TNF-α released by neutrophils can contribute to ROS

production and oxidative stress generation by specifically stimulating superoxide
production at the CoQ site of the electron transport chain in the mitochondria205. Small
concentrations of TNF-α and IL-6 cause a reduction in acetylcholine induced vasodilation
and increased production of endothelium derived contracting factors like ET-1206,

207

.

Also, estradiol, levels of which are high in pregnancy, enhances leukocyte binding to
endothelial cells via an increase in TNF-α induced adhesion molecules promoting further
neutrophil infiltration within the systemic vasculature of preeclamptic women. Neutrophil
release of TNFα might increase basal vascular tone by decreasing NO production and by
interfering with insulin-mediated vasodilatation in preeclampsia208.

E. Role of Matrix Metalloproteinase-1
Along with neutrophil infiltration and vascular inflammation, MMP-1 expression
is significantly increased in the vasculature of preeclamptic women (Estrada-Gutierrez,
Walsh, unpublished). Immunohistochemistry showed significantly greater staining for
MMP-1 in the endothelium, vascular smooth muscle and infiltrating leucocytes.
Consistent with a 7-fold increase in MMP-1 gene expression, pro-MMP-1 as well as
activated MMP-1, were more abundant in omental vessels from preeclamptic women as
compared to normal pregnant women. Moreover, plasma level of MMP-1 is also
significantly higher in preeclamptic women. Thus we wanted to examine a role for MMP1 in preeclampsia.
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MMP-1 is known for its collagenolytic properties and has been widely studied
with respect to its role as a collagenase. However, in recent years MMP-1 has been
shown to activate the protease activated receptor-1 (PAR-1)209,

210

, also known as

thrombin receptor. PAR-1 is a G-protein coupled receptor (GPCR) that is involved in a
number of cellular regulatory and signaling pathways. MMP-1 cleaves the N-terminal
end of PAR-1 two amino acids distal to the cleavage site of thrombin. This forms a new
N-terminus that binds to the tethered ligand binding site leading to PAR-1 activation211213

. MMP-1 induced N-terminal proteolytic cleavage resulting in irreversible PAR-1

activation is unique to PARs. Therefore PAR signaling is tightly regulated by rapid
desensitization at the plasma membrane by β-arrestins214, rapid phosphorylation and
receptor trafficking215.

In endothelial cells PAR-1 undergoes rapid agonist-induced

internalization, is delivered to lysosomes for degradation, and receptors from subcellular
location are translocated to the surface upon PAR-1 agonist stimulation216.

Our lab recently reported significantly increased PAR-1 expression in human
omental vessels from preeclamptic women with little to no PAR-1 expression in normal
pregnant women (Estrada-Gutierrez, Walsh, unpublished). Also endothelial cells express
PAR-1 and MMP-1 can cause PAR-1 mediated endothelial activation217. Thus in normal
pregnant women, MMP-1 can activate endothelial PAR-1 leading to endothelial cell
activation and release of endothelial cell granules containing vWF, IL-8 and ET-118.
Endothelin-1 is the only endothelin produced by endothelium and it acts on VSMC via
the ETA receptor to cause vasoconstriction and smooth muscle proliferation. Endothelin-1
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also contributes to increased vessel reactivity to vasoconstrictors like Ang II and NE.
Thus, MMP-1 can contribute significantly to the pathogenesis of preeclampsia by PAR-1
mediated endothelial activation and release of ET-1.
In

preeclampsia

neutrophils

could

be

a

source

of

MMP-1218,

as

immunohistochemistry staining for MMP-1 and neutrophils co-localize. However, our
lab has shown diffuse staining for MMP-1 within the vascular smooth muscle and that
neutrophils and neutrophil products like ROS and TNF-α induce MMP-1 expression by
VSMC in vitro (Estrada-Gutierrez, Walsh, unpublished). Vascular smooth muscle cells
express PAR-1219. Protease activated receptor-1 has also been implicated in increased
leucocyte endothelial adherance and rolling, migration of leukocytes from the vasculature
into inflamed tissues220 and causing edema via a breach in endothelial integrity221. Via
PAR-1 activation, our lab has shown that MMP-1 induces VSMC production of IL-8 and
collagen fragments, which are chemotactic to neutrophils and promote neutrophil
infiltration and vascular inflammation (Estrada-Gutierrez, Walsh, unpublished). Thus,
neutrophils and MMP-1 may be co-conspirators in the pathogenesis of preeclampsia.

F. Purpose of Investigation
Women who develop preeclampsia have enhanced vascular reactivity to Ang II
and decreased sensitivity to insulin. Neutrophil infiltration and vascular inflammation
was recently described within the systemic vasculature of preeclamptic women.
Neutrophils release toxic compounds like reactive oxygen species (ROS) and tumor
necrosis factor-alpha (TNF-α) that could adversely affect the vasculature.
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Neutrophil release of ROS might enhance vessel reactivity to Ang II. The primary
mechanism to enhance vessel reactivity is the RhoA kinase (ROK) pathway. ROK
phosphorylates MYPT1, the regulatory protein of MLC phosphatase. This inhibits MLC
phosphatase and thus inhibits de-phosphorylation of myosin light chains (MLC). The
resultant increase in phosphorylated MLC (pMLC) enhances vascular smooth muscle cell
sensitivity to intracellular calcium. ROS activate ROK, so neutrophils could enhance
vessel reactivity by release of ROS leading to activation of the ROK pathway.
Neutrophil release of ROS and TNFα might also adversely affect vascular
function by promoting insulin resistance as a result of down-regulating phosphatidyl
inositol 3-kinase (PI3K) and thus inhibiting GLUT-4 receptor translocation in vascular
smooth muscle cells. TNFα could down-regulate the activity and/or expression of PI3K
because it is the direct downstream target of insulin receptor substrate-1 and it is also
upstream of phosphorylated Akt, both of which are inhibited by TNFα. ROS might
down-regulate PI3K by activating RhoA, which inhibits PI3K/Akt signaling in
endothelial and vascular smooth muscle cells.
The following are the specific aims and hypotheses for my thesis dissertation,
which are designed to elucidate the role of neutrophils and neutrophil products in the
development of enhanced vessel reactivity to Ang II, vasoconstriction and insulin
resistance in preeclampsia.

G. Overall Hypothesis
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Specific Aim 1: To determine if neutrophils or neutrophil products, ROS and
TNFα, enhance vessel reactivity to vasoconstrictors like Ang II and NE.

Hypothesis 1: Activated neutrophils enhance vessel reactivity to Ang II.
Neutrophils isolated from healthy non-pregnant women will be activated with IL8 and perfused at physiologic concentration through the lumen of human omental
resistance arteries mounted on a myograph system. The vasoconstrictive response to Ang
II will be compared to the response in the absence of neutrophils. To determine the
mechanisms underlying enhanced vessel reactivity superoxide dismutase/catalase will be
used to quench ROS and Y-27632 to inhibit ROK.

Hypothesis 2: Neutrophil products, ROS and TNFα, will enhance vessel reactivity to
Ang II.
To test this hypothesis, human resistance arteries will be dissected from omental
fat obtained from normal pregnant women and mounted on a myograph system to assess
vasoconstrictive response to Ang II in the presence and absence of neutrophil products,
ROS and TNFα. Pharmacologic inhibitors, superoxide dismutase/catalase and Y-27632
will be used to determine the mechanism underlying neutrophil mediated enhanced vessel
reactivity to Ang II.
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Hypothesis 3: Neutrophils or neutrophil products will activate RhoA kinase in human
vascular smooth muscle cells as evidenced by increased phosphorylation of MYPT1 and
MLC.
To test this hypothesis, primary cultures of human vascular smooth muscle cells
will be co-cultured with neutrophils (activated using arachidonic acid) or treated with
neutrophil products, ROS and TNFα, for 24 hrs, after which cells will be harvested. The
cell lysates will be analysed using Western blotting to quantify the relative amounts of
phosphorylated and non-phosphorylated MLCs. Western Blotting using a specific
antibody to pMYPT1-Thr696 will be done for quantification of MYPT1 phosphorylation.
To test this hypothesis ex-vivo, human omental vessels will be dissected and treated with
ROS or Dulbecco’s phosphate buffered saline (D-PBS) alone. Within 5 minutes, the
vessels will be flash frozen in liquid nitrogen and processed for determination of RhoA
kinase activity using radioisotope labeled adenosine tri-phosphate (ATP) assay.

Hypothesis 4: ROS will enhance vessel reactivity to NE.
To test this hypothesis, human resistance arteries will be dissected from omental
fat obtained from normal pregnant women and mounted on a myograph system to assess
vasoconstrictive response to NE in the presence and absence of ROS. Pharmacologic
inhibition of RhoA kinase with Y-27632 will be used to determine if activation of RhoA
kinase underlies ROS mediated enhanced vessel reactivity to NE.
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Specific Aim 2: To determine if MMP-1 causes vasoconstriction or enhances vessel
reactivity to Ang II via activation of PAR-1 and ET-1 release from endothelium.

Hypothesis 1: MMP-1 causes dose-dependent vasoconstriction in human omental vessels.
To test this hypothesis, human resistance arteries will be dissected from omental
fat obtained from normal pregnant women and mounted on a myograph system to assess
vasoconstrictive response to varying doses of MMP-1. To determine the mechanisms
underlying MMP-1 induced vasoconstriction, SCH-79797, a PAR-1 inhibitor, and BQ123, an ETA receptor blocker, will be used.

Hypothesis 2: MMP-1 enhances vessel reactivity to Ang II.
To test this hypothesis, human omental fat arteries from normal pregnant women
will be used to assess vasoconstrictive response to varying doses of Ang II in the
presence and absence of a low dose of MMP-1. To determine the mechanism underlying
enhanced vessel reactivity, SCH-79797 and BQ-123 will be used.

Specific Aim 3: To determine if neutrophils or neutrophil products could cause
insulin resistance by affecting PI3K.
Hypothesis 1: Neutrophils and/or neutrophil products will decrease protein expression of
the regulatory (p85α) and catalytic (p110α) subunits of PI3K.
To test this hypothesis, human vascular smooth muscle cells will be co-cultured
with neutrophils (activated using arachidonic acid) or treated with neutrophil products,
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ROS and TNFα, for 48 hours, after which cells will be harvested and frozen at -80˚C
until analysis. The protein cell lysate will be analyzed by Western Blotting using specific
antibodies for the regulatory (p85α) and catalytic (p110α) subunits of PI3K. All
comparisons will be made to the control with culture medium alone.

In summary, my dissertation will examine if infiltration of neutrophils into the
systemic vasculature of preeclamptic women can explain the enhanced reactivity to Ang
II and insulin resistance characteristic of preeclampsia. It will also explore the
mechanisms by which neutrophils and neutrophil products enhance reactivity to Ang II
and determine if these phenomena are generalized or specific to Ang II. It will also
explore the role of MMP-1 in vasoconstriction and enhancement of vessel reactivity to
Ang II.

H. Significance of this research

If neutrophils or neutrophil products, ROS or TNF-α, are found to enhance vessel
reactivity to Ang II, then neutrophil infiltration and inflammation can explain the
increased vascular reactivity to Ang II in preeclampsia and provide the first explanation
for development of hypertension in preeclampsia. Moreover, if MMP-1 causes dose
dependent vasoconstriction or enhances vascular reactivity to Ang II, it may provide
alternate or additional evidence for explaining development of hypertension in
preeclampsia. If increased vessel reactivity to Ang II by neutrophils and ROS is mediated
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via the RhoA kinase pathway, the role of RhoA kinase inhibitors could be explored as
treatment options for preeclampsia. If MMP-1 causes vasoconstriction and enhances
vessel reactivity to Ang II via PAR-1 and ET-1, then PAR-1 inhibitors and ETA receptor
blockers could be studied for treatment of preeclampsia. If neutrophils are implicated in
the pathogenesis of preeclampsia, neutrophil-neutralizing antibodies are another
possibility that may be useful in preventing development or arresting progression of
preeclampsia by prevention of neutrophil adhesion and infiltration within the maternal
systemic vasculature.
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Figure 1. Theory of neutrophil activation in the intervillous space in placenta.
Neutrophils are activated as they circulate through the inter-villous space by lipid
peroxides secreted by the placental trophoblast cells. Neutrophils return to the maternal
compartment to cause vascular damage by generation of reactive oxygen species and
oxidative

stress. (Used with permission of artist. From Walsh, S. W. The role of

oxidative stress and anti-oxidants in preeclampsia. Contemporary OB/GYN, 1997; 42:
113-124)
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Figure 2. Pathways of neutrophil induced oxidative stress production. Interactions
between reactive oxygen intermediates and reactive nitrogen intermediates resulting in
nitric oxide (NO) scavenging by superoxide (O2.) production leading to formation of
peroxynitrite (ONOO-).
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Figure 3. Data redrawn from Gant et al (The Journal of Clinical Investigation, Nov
1973,Vol52, pg 2682-2689). This study clearly established development of sensitivity to
the pressor response of Angiotensin II during pregnancy as a predecessor to the
development of preeclampsia.
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Figure 4. RhoA kinase pathway. Release of reactive oxygen species (ROS) by activated
neutrophils may activate RhoA kinase (ROK) to result in phosphorylation (p) of the
regulatory myosin light chain (MLC) phosphatase target subunit 1 (MYPT1), which
inhibits the MLC phosphatase enzyme (MLCP). Inhibition of MLCP leads to decreased
MLC dephosphorylation, an accumulation of phosphorylated myosin light chains and
thus enhanced contraction for a given change in intracellular calcium level by the same
agonist concentration. (CaM-calcium calmodulin complex, MLCK- myosin light chain
kinase).
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Figure 5. Matrix metalloproteinase-1 (MMP-1) activation of PAR-1. MMP-1 induced
cleavage of the N-terminal end of the PAR-1 receptor generates a new N-terminal end
that allows inter-molecular interaction of the tethered ligand to the tethered ligand
binding site on the exo-domain of PAR-1, which results in activation of PAR-1.
Activation of endothelial PAR-1 can lead to endothelial activation with release of
endothelial cell granule contents like von Willebrand’s factor (vWF) and endothelin-1
(ET-1).

CHAPTER 2

MATERIALS AND METHODS

A. Myograph System:

i.

Collection of Fat

Omental fat biopsies (approximately 3 cm x 2 cm x 0.5 cm) were collected from
normal pregnant women and women with preeclampsia undergoing cesarean section at
Medical College of Virginia (MCV) Hospitals, Virginia Commonwealth University
(VCU) Medical Center. The fat was placed in a labeled bottle with isotonic normal saline.
The bottle was kept in a refrigerator and transferred to the laboratory on ice as soon as
possible. After the vessel arrived, it was immersed in cold (0-4˚C) Dulbecco’s Phosphate
Buffered Saline (D-PBS) containing glucose, sodium pyruvate, calcium chloride and
magnesium chloride (Gibco, Invitrogen) on a silicone dissection dish pre-cooled to 4˚C.

ii.

Vessel Dissection
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The fat biopsy was pinned down on the silicone dissection dish in cold (0-4˚C) DPBS to visualize the vasculature under a dissection microscope (Olympus, B061, zoom
1:7.5). A vessel of approximately 200-500 µ diameter was selected for dissection. The fat
around the vessel up to a length of 2 cm was dissected and discarded, while being careful
to leave about 1 mm of fat around the vessel to avoid damaging the vessel. Then, the
vessel was fixed on the dissection dish using two pins at either end. The artery was
identified from the vein (often the artery and vein ran together) (Fig.6). Fine dissection
was done using a 0.075 mm tip scissors (Fine Science Tools (FST) No.15001-08). Tissue
was held with Dumont #55 forceps (FST no.11255-20) and gently pulled away from the
artery. The scissors were used to cut the fat as close to the artery as possible, keeping the
cutting edge of the scissors parallel to the length of the artery and the curved tip of the
scissors pointing away from the artery. The artery was cleaned of adherent fat on all sides
making note of branch points and being careful not to puncture the vessel at any point
during dissection. A 1 cm length of vessel, free of branch points or potential punctures
was selected for mounting.

iii.

Mounting of the vessel

To mount the vessel on the myograph chamber (Fig.7) of the pressure myograph
(Danish Myo Technologies (DMT), Denmark, Netherlands, Fig.8), four double looped
ties were prepared using the suture tying forceps (FST 18025-10). Individual fibers
isolated from embroidery thread (Walmart Superstores) were used to prepare the ties. Ten

39
ml D-PBS was added to the myograph chamber. The glass cannulae at both ends were
tested for patency before mounting the vessel. The high vacuum grease which seals the
transducer pin hole was inspected before beginning the experiment and replaced every 2
weeks as per DMT recommendations. The myograph chamber was placed under the
dissecting microscope and two ties were looped over the P2 side glass cannula. Once the
selected vessel was mounted onto the tip of the P2 cannula, the ties were pulled over the
vessel and tightened by gentle pulling as excessive force can break the tip of the glass
cannula. Then, D-PBS was perfused through the vessel to gently flush out blood from the
vessel lumen. The process was repeated to secure the other end of the vessel on the P1
glass cannula (Fig.9). The myograph chamber was then placed on the stage of an inverted
microscope (Nikon Eclipse, TS100). Pressure and flow were applied using either the
DMT flow regulator or 10 ml syringes mounted at heights above the level of the vessel so
as to generate 45 and 42 mmHg pressures at the inlet and outlet, respectively. Syringes
reduced the amount of perfusate required to perfuse the vessel lumen to 10-15 ml as
compared to 250 ml required for the Schott bottle of the DMT flow regulator system.
When syringes were used flow was initiated from the P1 end with an inlet pressure of 45
mmHg with the syringe placed at a height of 61.2 cm above the vessel (13.6 mm H2O = 1
mmHg pressure) till D-PBS was seen to drip from the P2 end. Then, an outlet pressure of
42 mmHg with the syringe placed at a height of 57.12 cm above the vessel level was
applied at the P2 end.

iv.

Endothelium denudation
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For endothelium denudation, one end of the vessel was mounted onto the P1 side of a
glass cannula. The vessel was then gently pulled over the tip of the glass cannula over its
entire length and rolled gently. It was pulled back off the glass cannula leaving about 2
mm vessel length mounted onto the tip of the glass cannula. Then the two ties were
pulled over the vessel to secure the vessel onto the glass cannula, after which the vessel
lumen was gently flushed using D-PBS in a 1 ml syringe from the P1 end to flush out the
endothelial cells. The other end of the vessel was then mounted and secured onto the P2
side glass cannula.

v.

Data Recording

The microscope focus was adjusted to obtain a clear view of the vessel. After
connecting the Myo-Interface to the myograph chamber, the Myoview program on the
computer was started. The microscope focus was adjusted to obtain a clear view of the
vessel edges and lumen on the computer screen. Target inlet and outlet pressures were set
to 45 and 42 mmHg, respectively, on the computer screen. A box was drawn around the
vessel by clicking and dragging using the mouse for calibration by loading the 4X file (i.e
objective lens magnification used). A new box was drawn around the clean edges of the
vessel for analysis by the software. The graph configuration was set to a time range of
3600 seconds, data rate at 10 seconds, inflow pressure 0-60 mmHg, outflow pressure 060 mmHg, vessel diameter 200-600 µ, lumen diameter 50-500 µ, cross-sectional area 0-
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25000, and temperature to 0-40˚C. After graph configuration, history was reset and data
logging was started.

vi.

Pressure and Force calibration

Pressure and force calibration was performed periodically using a Big Ben
manometer and the weights as described in the DMT Manual (Model 110P & 111P,
version 3.2, pg 63-69).

B. PASM isolation and cell culture

Placental arterial smooth muscle (PASM) cells were isolated as described by Leik et
al222. Briefly, placentas were obtained from normal pregnant women after informed
consent (IRB# HM12361). The chorionic plate arteries were identified and dissected
away from the placental tissue. The vessel was cut longitudinally to open the arterial
lumen. The arterial sheet was cut into small pieces 3-5 mm, which were placed
endothelial surface down onto 10 cm culture plates. Five ml of Medium-199 (M-199,
Gibco, Invitrogen)) with 10% fetal bovine serum (FBS), 1% antibiotics and antimycotics
(100X Anti-Anti, Gibco Cat#15240-062, penicillin 100 U/ml, streptomycin 100 µg/ml,
amphotericin B 25 µg/ml) was added to the culture plates taking care not to disturb the
adherent explants. Cells started to grow from the explants at the end of 1 week and were
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confluent by about 4 weeks. At this point, they were exposed to M-199 without FBS for
24 hours to eliminate contaminating endothelial cells and fibroblasts, which do not
survive without serum. After 24 hours, PASM cells were replated with M-199 with 10%
FBS and then passaged or frozen. Cells were used between passage 2 and 6 (Fig.10).

C. Neutrophils, oxidative stress and TNF-α treatments:

Control: Control treatments were fresh M-199 medium with 10% FBS and 1%
antibiotics/antimycotics.
Neutrophils: Neutrophils were isolated from whole blood obtained from normal nonpregnant or normal pregnant women using Histopaque density gradient. For neutrophil
isolation, 3 ml of Histopaque 1119 (Sigma, Cat#11191) was added to 15 ml conical tube.
It was carefully layered with 3 ml of Histopaque 1077 (Sigma, Cat#10771) and then 6 ml
of whole blood. This was centrifuged at 700 x g for 30 minutes at room temperature (1826˚C) to form 5 distinct layers comprised of plasma, mononuclear cells with platelets,
histopaque 1077, granulocytes, histopaque 1119, and red blood cells (RBC) from top to
bottom [Fig.11]. Fluid to within 0.5 cm of the granulocyte layer was aspirated and
discarded. Cells from the granulocyte layer were aspirated and transferred to a new tube
labeled granulocytes. Ten ml phosphate buffered saline (PBS) was added and the cells
were centrifuged for 10 minutes at 200 x g at 4˚C. The PBS was removed with gentle
aspiration and the cell pellet re-suspended in 10 ml of PBS and centrifuged for 10
minutes at 200 x g at 4˚C. If the cell pellet had RBC’s, 3 ml of ice-cold ddH2O was added
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to the cell pellet followed by vortexing for 30 seconds to lyse the RBC’s. After 30
seconds, 1 ml of 0.6 M potassium chloride (KCl) was added to restore tonicity followed
by centrifugation at 200 x g at 4˚C for 4 minutes. The supernatant was discarded and the
cell pellet re-suspended in 1 ml of medium.
To count the neutrophils, 10 µl of cell suspension was added to 90 µl of trypan blue
dye and pipetted several times to mix well (dilution factor of 10). Ten µl of this 100 µl
cell suspension with dye was loaded onto a hemocytometer for counting. Neutrophils in
all four quadrants of the hemocytometer were counted and added together [4X=
X1+X2+X3+X4] (Fig.12). This number [4X] was divided by four to get the average
number of cells per square [X= X1+X2+X3+X4/4]. The concentration of neutrophils was
calculated as average number of cells per square x dilution factor x 104 neutrophils/ml.
Neutrophil activation was done using either 10-8 M IL-8 or 100 µM arachidonic acid. For
activation using IL-8, 10 µg of recombinant human IL-8 from R&D Systems (Cat# 208IL) is reconstituted in 1 ml of sterile phosphate buffered saline containing 1% bovine
serum albumin and aliquoted into aliquots containing 1 µg/100 µl. For a final
concentration of 10-8M IL-8, 80 µl of 1 µg/100µl aliquot is used per 10 ml of D-PBS
containing neutrophils. For activation using arachidonic acid, 10 µl of a 50 mg in 100 µl
ethanol solution was added to 1.08 ml of PBS to form Solution A. Then, 16.6 µl of
solution A was added to the 1 ml cell suspension and incubated in a rotator for 30
minutes at 37˚C.
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ROS: A reactive oxygen species (ROS) generating solution was made using 0.05 mM
hypoxanthine (Hyp, Sigma, H-9377) and 0.003 U/ml xanthine oxidase (XO, Calbiochem,
Cat#682151) in M-199 with 10% FBS. A 1 mM hypoxanthine stock solution was
prepared by dissolving 0.0027 gm of Hyp (MW 136.1) in 20 ml of M-199 with 1%
antibiotics-antimycotics and 10% FBS. Sonication for 30 minutes in a water bath was
used for dissolving the Hyp. For a final concentration of 0.05 mM, 250 µl of 1mM Hyp
solution was added to 4.75 ml of M-199 with 1% antibiotics/anti-mycotics and 10% FBS.
XO (Calbiochem) was purchased as a 20 U/ml stock solution made from buttermilk. For
culture, 0.75 µl of 20 U/ml XO was added to a T-25 flask containing 5 ml of M-199 with
1% antibiotics/anti-mycotics and 10% FBS for a final concentration of 0.003 U/ml.

TNF-α: To make a 1 ng/ml solution of TNF-α, 0.5 µl of 10 µg/ml recombinant human
TNF-α (R&D Systems, Cat#210-TA) was added to a T-25 flask containing 5 ml of media
[M-199 with 1% antibiotics/anti-mycotics and 10% FBS].

D. Protein extraction and quantification for Western blot

To detect phosphorylated proteins phospho-MYPT1 and phospho-MLC along
with total MYPT1 and MLC by Western blot, culture medium was carefully removed
from adherent PASM cells in T-25 flasks. One ml of ice cold PBS was added to each T25 flask and aspirated to remove FBS. M-PER (237 µl, Pierce 78501) with 3 µl of Halt
protease inhibitor cocktail (Pierce 78415) and 60 µl of phosphatase inhibitor cocktail set
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III (Calbiochem) was added to each T-25 flask. The flasks were placed on a shaker for 5
minutes. Cells were then scraped and the lysate transferred to a microcentrifuge tube to
be centrifuged at 14000 x g for 10 minutes at 4˚C. The supernatant was collected and
frozen at -80˚C. Protein concentration in the collected supernatant was quantified using
the Pierce BCA Protein Assay Kit.

E. Western blot methodology:

For all Western blots, the Invitrogen Xcell Surelock system was used for
electrophoresis and the Odyssey (Licor) system was used for scanning fluorescence
tagged secondary antibodies.
i. Sample Preparation: For MYPT1 and MLC, equal concentrations of protein for every
sample were calculated and volumized to 45 µl. Three µl of 20X reducing agent and 12 µl
of 5X Laemli’s were added. Samples were placed in boiling water at 100˚C for 15
minutes followed by cooling on ice and centrifugation at 4˚C for 1 minute. The samples
were then applied to the wells of the gel using gel loading pipette tips. Biorad All Blue
protein standards were run in the first lane of every Western blot.

ii. Antibodies, electrophoresis and transfer for phospho-MYPT1 & total MYPT1:

a) Primary antibodies:
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i) Rabbit polyclonal phospho-MYPT1 antibody (Cell signaling technologies, Cat#4563)
in a 1:300 dilution.
ii) Rabbit polyclonal MYPT1 antibody (Cell signaling technologies, Cat#2634) in a
1:1000 dilution.
iii) Mouse monoclonal anti-β actin Ig (Sigma, A2228) in a 1:10,000 dilution.

b) Secondary antibodies:
i) IRDye 800 anti-mouse antibody (Licor) in a 1:30,000 dilution
ii) AlexaFluor 680 goat anti-rabbit antibody (Invitrogen) in a 1:2500 dilution

Tris-Glycine SDS gels (6%) were cast using the Biorad casting system and 1.5 mm
combs. For a 15 ml gel, 7.9 ml ddH2O, 3.0 ml 30% acrylamide mix, 3.8 ml 1.5 M Tris at
pH 8.8, 0.15 ml of 10% SDS, 0.15 ml of 10% ammonium persulfate (Fischer, BP179-25)
and 12 µl of TEMED (N, N, N’, N’- Teramethylethylenediamine from Sigma, T9281).
With sample loading of at least 50 µg protein/well, electrophoresis was run at 125V for 1
hour 50 minutes. After electrophoresis, the gel was washed with ddH2O followed by
equilibration in methanol free transfer buffer for 15-20 minutes. PVDF membrane (0.45µ
pore size, Millipore) was wetted in 100% methanol for 30 seconds followed by rinsing in
ddH2O and equilibration in methanol free transfer buffer for 15 minutes. Ice cold
methanol free transfer buffer was used to soak the blotting pads taking care to remove all
air bubbles. The sandwich of blotting pads, gel and PVDF membrane was assembled and
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transfer was run for 2.5 hours at 70V. Coomasie blue staining of the gel was used to
confirm optimal transfer of protein.

iii. Antibodies, electrophoresis and transfer for phospho-MLC and total MLC:

a) Primary antibodies:
i)

Rabbit polyclonal phospho myosin light chain 2 (Ser19) antibody (Cell signaling
technologies, Cat#3671) in a 1:3000 dilution.

ii)

Rabbit polyclonal myosin light chain 2 antibody (Cell signaling technologies,
Cat#3672) in a 1:1000 dilution.

iii)

Mouse monoclonal anti-β actin Ig (Sigma, A2228) in a 1:10,000 dilution.

b) Secondary antibodies:
i)

IRDye 800 anti-mouse antibody (Licor) in a 1:30,000 dilution.

ii)

AlexaFluor 680 goat anti-rabbit antibody (Invitrogen) in a 1:10,000 dilution.
Tris-Glycine SDS gels (12%) were cast using the Biorad casting system and 1.5 mm

combs. For a 15 ml gel, 4.9 ml ddH2O, 6.0 ml 30% acrylamide mix, 3.8 ml 1.5 M Tris at
pH 8.8, 0.15 ml of 10% SDS, 0.15 ml of 10% ammonium persulfate (Fischer, BP179-25)
and 6 µl of TEMED (Sigma, T9281). With sample loading of at least 50 µg protein/well,
electrophoresis was run at 125V for 1 hour 50 minutes. After electrophoresis, the gel was
washed with ddH2O followed by equilibration in methanol free transfer buffer for 15-20
minutes. PVDF membrane (0.2µ pore size, Millipore) was wetted in 100% methanol till
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the opaque membrane turned a translucent gray color, followed by rinsing in ddH2O and
equilibration in 40% methanol transfer buffer for 15 minutes. Ice cold 40% methanol
transfer buffer was used to soak the blotting pads taking care to remove all air bubbles.
The sandwich for transfer was assembled and transfer run for 1.5 hours at 25V.
Coomassie blue staining of the gel was used to confirm optimal transfer of protein. The
membrane was immersed in 0.25% glutaraldehyde at room temperature for 45 minutes to
fix the myosin light chains and washed with PBS before proceeding with blocking.

iv. Primary and secondary antibody incubation

For all Western blots, the membrane was marked with pencil, cut or fold to identify
the face of the membrane in approximation with the gel. The membrane was washed in
ddH2O for 5 minutes and blocked in 1:1 diluted Odyssey Blocking buffer (Licor) and
PBS for 1 hour at room temperature. The membrane was then washed once with PBS for
5 minutes. After that, the membrane was incubated overnight at 4˚C in the primary
antibody solution comprised of 1:1 PBS and Odyssey Blocking Buffer with 0.1% Tween20. The next day the membrane was washed 4 times for 5min each in PBS with 0.1%
Tween-20. Henceforth, foil wrap was used to protect the membrane from light. The
membrane was incubated for 1 hr at room temperature with secondary antibody solution
in 1:1 PBS and Odyssey blocking buffer with 0.1% Tween-20 and 0.01% w/v of SDS.
The membrane was washed 4 times for 5 minutes each in PBS with 0.1% Tween-20.
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Then the membrane was washed 4 times for 5 minutes each in PBS alone and twice for 5
minutes each in ddH2O. The membrane was scanned using the Odyssey system. The
glass and silicon mat were cleaned before placing the membrane on the Odyssey scanner.

v. Membrane stripping using low pH:

A stripping buffer of 25 mM glycine-HCl at pH 2.0 with 1% SDS was prepared by
addition of 1.88 gm glycine and 10 gm SDS to 600 ml ddH2O and titrated to a pH of 2.0
using 1 N HCl. It was then volumized to 1 L with ddH2O. For membrane stripping, the
membrane was placed in the stripping buffer for 30 minutes with agitation and then
washed in PBS for 10 minutes twice. After stripping, blocking of the membrane for the
next antigen detection step was performed.

vi. Densitometric analysis

Quantification of bands obtained on Western blots was done by densitometric
analysis of the bands in the ‘Details View’ of the Odyssey software using the median
method for calculation of background. The average intensity obtained for each band was
normalized to that of β-actin for the same lane. The band intensity of each treatment was
then calculated as a percent value of the normalized value of the control lane for that
experiment. The percent value of the control was used for statistical analysis.
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U -shaped
Vein

Artery

V-shaped

Figure 6. Identification of the artery. The artery can be identified from the vein by
looking for branch points. Branches off the artery are sharp and shaped like a V while
those from veins are U-shaped. The vein is collapsible on pressure and shows slow or no
return of blood flow when pressed against. Pressing the artery against the silicone dish to
judge thickness of the vessel wall and return of blood flow damages the vessel, so a
length of vessel distal or proximal but not including the area pressed should be used for
the experiment. The artery is usually the narrower of the two vessels.
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Perfusion
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Pipe for oxygen supply

Extra perfusion inlet

Figure 7. Myograph Chamber. Pressure myograph system with in-built pressure and
force transducers and a perfusion system with inlet (P1) and outlet (P2) (From DMT
manual, model 110P & 111P, version 3.2).
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Figure 8. DMT Pressure Myograph. The equipment comprised of the myograph
chamber placed on the stage of the inverted microscope and connected with the
Myointerface and the flow and pressure regulator placed on top of the Myointerface
with Schott bottles for perfusion of the vessel. The Myointerface connects the
myograph chamber to the computer enabling data recording and control of the
myograph chamber through the computer program settings.
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Figure 9. Myoview image of the mounted vessel, showing the tip of the glass cannula
within the vessel lumen.
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Table 1. Configuration settings of the software used for myograph experiments
Time range (s) 3600

Data Rate(s) 10

Inflow pressure (mmHg)

0

60

Outflow Pressure (mmHg)

0

60

Vessel diameter (microns)

250

500

Lumen diameter (microns)

50

500

Cross-sectional Area

0

25000

Temperature (C)

0
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A

B

C

D

Figure 10. Placental arterial smooth muscle (PASM) cell culture. PASM cells growing
from chorionic plate arterial explants at A) 1 week, B) 2 weeks, C) 3 weeks and D) 4
weeks.
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Centrifuge
700g 30min
Whole Blood

Histopaque

1077

Histopaque 1119

Plasma
Monocytes/lymphocytes
1077
Granulocyte /neutrophils
Histopaque

Histopaque

1119

Erythrocytes

Figure 11. Neutrophil Isolation by Histopaque Gradient Separation. The top layers up to
0.5 cm above the granulocyte (neutrophil) layer were aspirated and discarded. The
neutrophil layer was then aspirated and transferred to a new tube to be washed with PBS.
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X1

X2

X3

X4

Figure 12. Cell counting grid of hemocytometer: Count all neutrophils within the red
boxes and add them together (4X). Divide this number by 4 to get X. The volume of
each square with the coverslip in place is 0.1 mm3. Therefore, cells per ml = average
count per square x dilution factor x 104.

Chapter 3

NEUTROPHILS ENHANCE VASCULAR REACTIVITY TO ANGIOTENSIN II
VIA REACTIVE OXYGEN SPECIES ACTIVATION OF THE RHOA KINASE
PATHWAY

A. Introduction

Preeclampsia is a hypertensive disorder of pregnancy that complicates 5-7% of all
pregnancies resulting in significant maternal and fetal mortality and morbidity5.
Recently, we showed significant infiltration of neutrophils into systemic vasculature of
women with preeclampsia, which was associated with marked vascular inflammation95,
96

. We also found a similar vascular infiltration of neutrophils in obese women97 which

may be of interest because obesity is a risk factor for preeclampsia, as well as chronic
hypertension223.

In 1973, Gant et al described enhanced vascular reactivity to angiotensin II (Ang
II) in women predestined to develop preeclampsia123. However, mechanisms underlying
this increased vascular reactivity remained elusive. The major mechanism of increased
vascular reactivity is the RhoA kinase (ROK) pathway and reactive oxygen species

(ROS) activate this pathway

134
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. When ROK is activated, it phosphorylates MYPT1 which

inhibits myosin light chain phosphatase so myosin light chains (MLC) remain
phosphorylated which enhances vascular reactivity.134 Therefore, for a given
concentration of Ang II, vessel responsiveness would be enhanced. Neutrophils release
inflammatory compounds that could cause vasoconstriction or enhance vessel reactivity
to vasoconstrictors. For example, neutrophil release of ROS may enhance vessel
reactivity by RhoA kinase pathway activation.

In this study we used human omental vessels and cultured human vascular smooth
muscle cells to test the hypothesis that neutrophils or neutrophil products (ROS, TNF-α)
cause vasoconstriction by enhancing vessel reactivity to Ang II via the RhoA kinase
pathway.

B. Materials and Methods

Study Subjects
Omental fat biopsies (approximately 2 cm x 4 cm x 2 cm) were collected from
normal pregnant women undergoing term C-section at MCV Hospitals, Virginia
Commonwealth University Medical Center. Omental fat is vascularized tissue
representative of the systemic vasculature. Neutrophils were isolated from whole blood of
pregnant or non-pregnant female subjects using dual Histopaque (Sigma, St. Louis, MO)
density gradient centrifugation as previously described191. Demographic data on the
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subjects were (Mean±SD): age (27.5±6 years), systolic blood pressure (127±16 mmHg),
diastolic blood pressure (74±11 mmHg), gestational age (39±1 weeks), birth weight
(3387±506 grams). Twenty-one subjects were primiparous and 19 were multiparous.
Mean lumen diameter of omental vessels studied was 287 ± 99 µ. The Office of Research
Subjects Protection of Virginia Commonwealth University approved this study and all
subjects gave informed consent. IRB No. HM12361

Myograph Experiments
The omental fat biopsy was placed in Dulbecco’s phosphate buffered saline (DPBS, Gibco Invitrogen, Carlsbad, CA) on a silicone dissection dish pre-cooled to 4˚C. A
2 cm length of a vessel 200-500 µ diameter was dissected and mounted on glass microcannulae of a myograph system (Model 110P, Danish Myo Technologies (DMT),
Denmark, Netherlands). Endothelium was denuded by passing a fine metal wire through
the vessel lumen. The vessel was immersed in 10 ml of D-PBS in the myograph chamber
and secured at both ends using two 11-O silk suture ties at each end. The myograph
chamber temperature was maintained at 37˚C and the vessel pressures maintained at
constant inlet (45 mmHg) and outlet (42 mmHg) pressures to achieve flow through the
vessel. Ang II dose response was run in 10-fold increments in concentrations 0.001-10
µM. The vessel was challenged to 60µM KCl at beginning, end and in between
treatments to ascertain vessel viability and to recharge intracellular calcium stores.
Isolated neutrophils were re-suspended in 1 ml of D-PBS and counted using a
hemocytometer. Neutrophils were activated using human recombinant interleukin-8 (IL-

-8

8, 10
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M final concentration, R&D Systems, Minneapolis, MN). Neutrophils were

perfused through the vessel in a physiologic concentration of ~2000/mm3 and after noting
response to neutrophils alone the Ang II dose response was repeated. The experiment
was repeated in the presence of either superoxide dismutase (SOD, 5000 IU/ml, Sigma,
St. Louis, MO) and catalase (150 U/ml, Sigma, St. Louis, MO) or Y-27632 (3 µM,
Calbiochem, Gibbstown, NJ), a specific RhoA kinase inhibitor, in the D-PBS bath along
with perfusion of activated neutrophils in lumen. ROS generating solution composed of
0.05 mM hypoxanthine (Hyp, Sigma, St. Louis, MO) and 0.003 U/ml xanthine oxidase
(XO, Calbiochem, Gibbstown, NJ) was added to the vessel chamber and after a period of
stabilization, Ang II dose response was repeated. Ang II dose response was repeated
again in the presence of either SOD/catalase or Y-27632 along with ROS in the bath. Ang
II dose response was also tested in the presence of TNF-α (1 ng/ml). To determine if
ROS mediated enhanced reactivity was specific to Ang II or a non-specific phenomenon,
norepinephrine (NE) dose response was run in 2-fold increments (0.15625 µM to 5 µM)
and repeated in the presence of ROS generating solution. Response to Y-27632 and ROS
was tested at a single dose of 1.25 µM NE.

Western Blot
Primary human vascular smooth muscle cells (VSMC) were isolated from
placental chorionic plate arteries and cultured as described in Chapter 2. VSMC were
grown to confluence in T-25 flasks in M-199 with 10% FBS. Cells were treated for 5
minutes with Ang II alone or with Ang II plus activated neutrophils (50,000
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neutrophils/ml) or Ang II plus ROS with and without Y-27632 (3 µM). ROS generating
solution was composed of 0.05 mM Hyp and 0.003 U/ml XO. Western blot was
performed for Ser19-pMLC and total MLC (Cell Signaling technologies, 1:2000,
Beverly, MA) along with Thr696-pMYPT1 (Santa Cruz, 1:1000) and total MYPT1 (Cell
Signaling technologies, 1:500). Blots were scanned and quantified using the Licor
Odyssey system. β-Actin was used to normalize data.

Immunokinase Assay to determine RhoA Kinase Activity
Equal amounts of omental vessels were dissected and weighed into two 0.5 ml
centrifuge tubes and treated with D-PBS alone (control) or D-PBS with a ROS generating
solution composed of 0.05 mM Hyp and 0.003 U/ml XO for 5 minutes. At the end of 5
minutes the vessels were flash frozen in liquid nitrogen and stored at -80˚C until the
RhoA Kinase activity assay was run as described previously224. Briefly, 20 µl of Rho
kinase immunoprecipitates were added to the reaction mixture containing 1 mM
adenosine triphosphate (ATP) and 10 µCi of [γ-32P] ATP (3000 Ci/mol) along with 5 µg
of myelin basic protein, followed by incubation for 15 min at 37˚C. Phosphorylation of
myelin basic protein was absorbed onto phosphocellulose disks, and free radioactivity
was removed by washing 3 times with 75 mM phosphoric acid (H3PO4). The amount of
radioactivity on the disks was measured using liquid scintillation. The results are
expressed as counts per minute per milligram protein.

Data Analysis
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The myograph experimental data were analyzed by one-way ANOVA and
Bonferroni post-hoc test for each dose of Ang II due to significant interaction detected by
the two-way ANOVA. The myograph experimental data for each dose of NE were
analyzed using repeated measures two-way ANOVA with Bonferroni post-test. The
western blot data were quantified using the average intensity measurements normalized
to β- actin and then calculated as a percentage of the control value. The RhoA kinase
immunoassay data were analyzed using the Mann Whitney test. A statistical software
program was used (Prism 4, GraphPad software, San Diego, CA). All data are presented
as mean ± SE.

C. Results

Effect of Neutrophils
As shown in Figure 13, dose response to Ang II alone ranged from a 4 µ decrease
in vessel diameter with 10-9 M Ang II up to a 14 µ decrease with 10-6 M Ang II. When
neutrophils were perfused through the vessel lumen and Ang II dose response was
repeated, vascular reactivity to Ang II was significantly enhanced at all doses (Fig.14).
The vessel diameter decreased by an average of 46 µ with 10-5 M Ang II in the presence
of activated neutrophils in the vessel lumen. Addition of SOD/Catalase to the myograph
chamber to quench ROS significantly blocked enhanced vascular reactivity to Ang II
(Fig.15). The specific RhoA kinase inhibitor, Y-27632, also abolished enhanced vascular
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reactivity to Ang II in the presence of neutrophils (Fig.16). Perfusion with either IL-8
alone or un-activated neutrophils did not affect the Ang II dose response.

Effect of ROS and TNF-α
As shown in Figure 17, addition of a ROS generating solution to the myograph
chamber significantly enhanced vascular reactivity to Ang II similar to that seen with
perfusion of activated neutrophils. Endothelium intact vessels also showed a significant
increase in vessel reactivity to Ang II in the presence of ROS. However, the response was
attenuated because of endothelial compensatory mechanisms as would be expected
(Fig.17 B). Also similar to neutrophils, addition of SOD/Catalase (Fig.18) or Y-27632
(Fig.19) significantly inhibited ROS induced enhancement of vascular reactivity to Ang
II. ROS generating solution by itself caused contraction of only -2.67±1.61 µ.
Contraction induced by ROS alone was excluded for measurement of enhanced vascular
reactivity to Ang II. In contrast to ROS, TNF-α, another neutrophil inflammatory product
did not alter vascular reactivity to Ang II (Fig.20, N=4, p>0.1).

Effect of Neutrophils and ROS on RhoA kinase activity and expression of pMYPT1 and
pMLC
Human omental vessels treated with a ROS generating solution for 5 minutes
showed a significant increase in RhoA kinase activity as compared to control (Fig.21). To
confirm increased RhoA kinase activity, the effect of ROS and neutrophils on
phosphorylation of MYPT1 and MLC was evaluated by Western blot in VSMC.
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Treatment with ROS plus Ang II or neutrophils plus Ang II increased phosphorylation of
MYPT1 which is the protein directly phosphorylated by RhoA kinase. Y-27632 inhibited
phosphorylation of MYPT1 by ROS and neutrophils (Fig.22). As shown in Fig.23,
treatment of VSMC with ROS or neutrophils in the presence of Ang II significantly
increased phosphorylation of MLC, which is consistent with inhibition of myosin light
chain phosphatase by pMYPT1. Phosphorylation of MLC was reduced by Y-27632.
Treatment of VSMC with Ang II alone did not significantly increase phosphorylation of
MYPT1 or MLC over control.

Norepinephrine Dose Response
As shown in Fig. 24A, ROS significantly enhanced the vasoconstrictive response
to all doses of NE tested (N=6, p<0.001) except the 0.3125 µM dose. At 1.25 µM dose
the increase in vasoconstrictive response to NE by ROS was significantly inhibited by
addition of Y-27632 (Fig. 24B, N=4, p<0.05).

D. Discussion
In this study we demonstrate that vascular reactivity of human omental vessels to Ang II
is markedly increased in the presence of ROS in both endothelium intact and endothelium
denuded vessels. Enhancement of vascular reactivity was less in the presence of
endothelium as would be expected due to endothelial compensatory factors such as nitric
oxide and prostacyclin. Removal of the endothelium enabled the study of direct effects of
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ROS on the vascular smooth muscle contractile apparatus without activation of
endothelial pathways, and so was used for neutrophil experiments. Increased vessel
reactivity to Ang II was due to ROS because co-treatment with SOD/catalase to quench
ROS completely inhibited enhanced vessel reactivity to both ROS and neutrophils. The
enhancement to ROS was via the RhoA kinase pathway because the enhanced response
was abolished by using a specific RhoA kinase inhibitor. This was confirmed with exvivo omental vessels treated with ROS showing increased Rho kinase activity as well as
in cell culture experiments using human vascular smooth muscle cells which
demonstrated increased phosphorylation of MLC and MYPT1 in the presence of ROS or
neutrophils. The enhanced vessel responsiveness to Ang II was specific to ROS as
another neutrophil product, TNFa, was ineffective. The ability of ROS to enhance
vascular reactivity via the RhoA kinase pathway was not limited to Ang II as ROS also
enhanced vascular reactivity to NE, another vasoconstrictor. NE release is induced by
stress and sympathetic activation, factors reported to be associated with preeclampsia153155

. Our findings of enhanced vessel reactivity to Ang II and NE in the presence of ROS

or neutrophils may explain hypertension in pregnancy and why women who are destined
to develop preeclampsia have an increased sensitivity to Ang II before clinical symptoms
of hypertension are manifest123.
Our findings may extend to hypertension in non-pregnant as well as pregnant
subjects because RhoA kinase has been shown to play a critical role in chronic
hypertension139, 225. Obesity is a known risk factor for chronic hypertension, as well as
preeclampsia223, and we recently reported extensive systemic vascular infiltration of
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neutrophils in obese women . The vascular phenotype of the obese women was similar
97

to that of preeclamptic women. Thus, vascular infiltration of neutrophils may help
explain the relationship between obesity and hypertensive disorders, such as chronic
hypertension and preeclampsia.
Our recent finding of extensive vascular infiltration of neutrophils in women with
preeclampsia95,
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challenged conventional thinking because neutrophils are usually

thought of as part of the innate immune system and the first line of defense against
infection at the site of a wound53

226

. A role for neutrophils in non-infectious disease has

not been widely studied, but accumulating evidence indicates a role for neutrophils in
“sterile” inflammatory diseases227.
The reason neutrophils may be playing an important role in pregnancy is that in
normal pregnancy, the number of neutrophils increases 2.5-fold by 30 weeks of gestation
228

and this number increases further in preeclampsia

54

. The human placenta produces

oxidized lipids and secretes them into the maternal circulation

36, 38, 69, 159, 229

. Oxidized

lipids are potent activators of neutrophils 66, 68, 191. In women with preeclampsia, placental
production of oxidized lipids is significantly higher than in women with normal
pregnancy38. One possibility for neutrophil activation occurs as they circulate through the
intervillous space and are directly exposed to oxidized lipids released by the placenta36,
230, 231

.

Activated neutrophils in the maternal systemic circulation adhere to the

endothelium and could cause vascular inflammation and dysfunction by release of toxic
compounds. Neutrophil release of matrix metalloproteinase-8 and myeloperoxidase could
compromise vascular integrity, and that coupled with increased hydrostatic pressure as a
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result of enhanced vascular reactivity to Ang II, could promote extravasation of proteins.
Thus, neutrophil infiltration may contribute not only to hypertension, but also to edema
and proteinuria in preeclampsia.
This is the first study to show that neutrophils enhance vascular reactivity by
activating RhoA kinase pathway and the first to show that ROS activate RhoA kinase in
human vessels. Our findings are highly significant with respect to hypertension, as
resistance is inversely proportional to the fourth power of the radius, so even small
decreases in vessel diameter cause large increases in resistance. For example, in our study
the highest dose of Ang II caused a 28% increase in resistance. In the presence of ROS or
neutrophils, Ang II caused a 101% or 115% increase in resistance, respectively, which
was approximately a 4 fold increase in resistance over that with Ang II alone.

Perspectives
These data are the first to show that both ROS and neutrophils enhance vessel
contractility to Ang II and NE and provide evidence that the mechanism of ROS and
neutrophil enhanced Ang II reactivity is by activating RhoA kinase. These data support
the idea that neutrophil infiltration into systemic vasculature of preeclamptic women may
be a cause of hypertension. There is no definitive treatment for preeclampsia, but these
new data could provide novel avenues for treatment based on regulation of neutrophil
infiltration. Potential treatments that are becoming available for clinical studies are
neutralizing antibodies against adhesion molecules and selective RhoA kinase inhibitors.
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Angiotensin II facilitates norepinephrine release from sympathetic nerve endings and
prevents norepinephrine re-uptake and thus enhances sympathetic adrenergic activity.
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Figure 13. Vessel reactivity to Ang II alone. Ang II (0.001 µM) caused a mean
vasoconstriction of 7 µ while maximum mean vasoconstriction of 20 µ was obtained
with 1 µM Ang II (N=20).
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Figure 14. Vessel reactivity to Ang II in the presence of neutrophils. Perfusion of
activated neutrophils (<2000/mm3) through the vessel lumen significantly enhanced
vessel reactivity to Ang II. Ang II (0.001 µM) caused a mean vasoconstriction of 12 µ
while maximum mean vasoconstriction of 50 µ was obtained with 10 µM Ang II in the
presence of neutrophils (N=10, ** p<0.01, *** p<0.001).
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Figure 15. Role of ROS in enhancing vessel reactivity to Ang II by neutrophils. Addition
of SOD/catalase to quench ROS abolished enhancement of vessel reactivity to Ang II by
neutrophils. (N= 4, ** p<0.01, *** p<0.001).
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Figure 16. Role of RhoA kinase pathway in enhancing vessel reactivity to Ang II by
neutrophils. Addition of Y-27632, a specific RhoA kinase inhibitor, abolished
enhancement of vessel reactivity to Ang II by neutrophils. (N= 4, * p<0.05, ** p<0.01).
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Figure 17. Vessel reactivity to Ang II in the presence of ROS. Addition of a ROS
generating solution in the bath significantly enhanced vessel reactivity to Ang II, similar
to that seen with neutrophils. A) In endothelium denuded vessels, Ang II (0.001 µM)
caused a mean vasoconstriction of 12 µ while maximum mean vasoconstriction of 48 µ
was obtained with 10 µM Ang II in the presence of ROS (N=17, ** p<0.01, ***
p<0.001). B) In endothelium intact vessels, Ang II (0.001 µM) caused a mean
vasoconstriction of 8 µ while maximum mean vasoconstriction of 25 µ was obtained with
10 µM Ang II in the presence of ROS (N=6, * p<0.05, ** p<0.01).
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Figure 18. Specificity of ROS in enhancing vessel reactivity to Ang II. Addition of
SOD/catalase to quench ROS abolished enhancement of vessel reactivity to Ang II. (N=
4, * p<0.05, ** p<0.01).
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Figure 19. Role of RhoA kinase pathway in enhancing vessel reactivity to Ang II by
ROS. Addition of Y-27632, a specific RhoA kinase inhibitor, abolished enhancement of
vessel reactivity to Ang II by ROS. (N= 4, * p<0.05, ** p<0.01).
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Figure 20. Vessel reactivity to Ang II in the presence of TNF-α. Addition of 1 ng/ml of
TNF-α in the bath did not significantly affect vessel reactivity to Ang II (0.001 µM to 10
µM, N=17).
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Figure 21. RhoA kinase activity in human omental vessels. RhoA kinase activity in
omental vessels treated with ROS showed a 3-fold increase as compared to control (N=5,
** p<0.01).
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Figure 22. Thr-696 pMYPT1 (phosphorylated regulatory target sub-unit of myosin light
chain phosphatase) expression in cultured human vascular smooth muscle cells. A)
Representative Western blot of pMYPT1 and total MYPT1 normalized to β-actin in
cultured human VSMC. B) Mean band density of pMYPT1 expression normalized to βactin and plotted as percentage of control. VSMC were treated with control media, Ang II
alone, Ang II plus ROS generating solution or activated neutrophils with and without Y27632 (Y) for 5 min. Treatment with ROS or activated neutrophils significantly enhanced
phosphorylation of MYPT1 which was inhibited by Y-27632 (N=3, * p<0.05).
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Figure 23. Expression of Ser-19 pMLC (phosphorylated myosin light chain) in cultured
human vascular smooth muscle cells. A) Representative Western blot of pMLC and total
MLC normalized to β-actin in cultured human VSMC. B) Mean band density of pMLC
expression normalized to β-actin and plotted as percentage of control. VSMC were
treated with control media, Ang II alone, Ang II plus ROS generating solution or
activated neutrophils with and without Y-27632 (Y) for 5 min. Treatment with ROS or
activated neutrophils significantly enhanced phosphorylation of MLC which was
inhibited by Y-27632 (N=5, * p<0.05).
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Figure 24. Vessel reactivity to norepinephrine (NE). A) Dose response of vessel
reactivity to NE was significantly enhanced in the presence of ROS compared to NE
alone (N=6, ***p<0.001). B) Addition of Y-27632 (Y) abolished enhanced vessel
reactivity to NE in response to ROS at 1.25 µM dose of NE (N=4, *p<0.05).

Chapter 4

MATRIX METALLOPROTEINASE-1 CAUSES DOSE DEPENDENT
VASOCONSTRICTION AND ENHANCES VESSEL REACTIVITY TO
ANGIOTENSIN II VIA PROTEASE ACTIVATED RECEPTOR-1 AND
ENDOTHELIN-1

A. Introduction
Preeclampsia is a hypertensive disorder of pregnancy that complicates 5-7% of all
pregnancies resulting in significant maternal and fetal mortality and morbidity5.
Recently, we showed significant increase in plasma MMP-1 level and MMP-1 expression
in the vasculature of women with preeclampsia (Estrada-Gutierrez, Walsh, unpublished).
Consistent with a 7-fold increase in MMP-1 gene expression, pro-MMP-1 as well as
activated MMP-1 were more abundant in omental vessels from preeclamptic women as
compared to normal pregnant women. Immunohistochemistry showed significantly
greater staining for MMP-1 in the endothelium, vascular smooth muscle and infiltrating
leukocytes in subcutaneous fat blood vessels of preeclamptic women.
Increased vascular expression of MMP-1 may be responsible for the edema and
protein leakage in preeclampsia due to its ability to degrade type 1 collagen. However,
MMP-1 has recently been shown to activate protease activated receptor-1 (PAR-1) also

known as thrombin receptor
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. Activation of endothelial PAR-1 results in

209, 210, 212, 213

release of endothelin-1 (ET-1)217, which is a potent vasoconstrictor and can enhance
vascular reactivity to angiotensin II (Ang II)198.

In this study, we tested a novel hypothesis that MMP-1 has vasoconstrictive
properties via activation of PAR-1 and release of ET-1. To test this hypothesis we used
human omental vessels and a pressure myograph system to record real time changes in
vessel diameter in response to MMP-1. We also tested if MMP-1 enhances vessel
reactivity to Ang II.

B. Materials and Methods

Study Subjects
Omental fat biopsies (approximately 2 cm x 4 cm x 2 cm) were collected from 21
normal pregnant women undergoing term C-section at MCV Hospitals, Virginia
Commonwealth University Medical Center. Omental fat is a highly vascularized tissue
containing resistance vessels representative of the systemic vasculature. Demographic
data on the subjects were (Mean±SD): age (28.5±6 years), systolic blood pressure
(126±15 mmHg), diastolic blood pressure (77±10 mmHg), gestational age (39±1 weeks),
birth weight (3379±444 grams). Sixteen subjects were primiparous and 5 were
multiparous. Mean lumen diameter of omental vessels studied was 281 ± 70 µ. The
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Office of Research Subjects Protection of Virginia Commonwealth University approved
this study and all subjects gave informed consent. IRB No. HM12361.

MMP-1 Activation
All MMPs are produced in a latent form (pro-MMP or zymogen) and require
activation. Commercially obtained human pro-MMP-1 (Calbiochem 444208; Stock 80
µg/ml) was activated using amino-phenyl mercuric acetate (APMA, Calbiochem
164610). A 10 mM APMA solution was prepared by dissolving 35.18 mg APMA in 0.1
M sodium hydroxide (NaOH). This 10 mM APMA is stable for 1 week at 4˚C. To initiate
activation, 5 µl of pro-MMP-1 (400 ng) was diluted with 85 µl of Tris-Triton-Calcium
(TTC) buffer and 10 µl of 10 mM APMA for a final volume of 100 µl. This was
incubated for 2 hours at 37˚C. TTC buffer was 50 mM Tris-hydrochloride (Tris-HCl) at
pH 7.5 with 1 mM calcium chloride (CaCl2) and 0.05% Triton X-100. For APMA
elimination, a Microcon Centrifugal Filter Device, Ultracel YM-10 (10,000 MW), was
blocked with 100 µl of 1 mg/ml bovine serum albumin (BSA) for 30 min at 37˚C. Then,
after addition of 100 µl of D-PBS, it was centrifuged at 11,000 x g for 20 minutes at 4˚C.
The filter device was then inverted onto a new tube, spun briefly and left to dry. Then,
100 µl of MMP-1 mixture was transferred to the blocked filter device, and after adding
200 µl of D-PBS, it was centrifuged at 11,000 x g for 20 minutes at 4˚C to wash out the
APMA. The filtrate was discarded and this step repeated to ensure maximal removal of
APMA. The filter device was then inverted on a new tube and spun briefly. The
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recovered activated MMP-1 was diluted to a total volume of 100 µl to give a final
concentration of 400 ng/100 µl.

Myograph Experiments
The omental fat biopsy was placed in Dulbecco’s phosphate buffered saline (DPBS, Gibco Invitrogen, Carlsbad, CA) on a silicone dissection dish pre-cooled to 4˚C. A
1 cm length of a vessel 200-500 µ diameter was dissected and mounted on glass microcannulae of a myograph system (Model 110P, Danish Myo Technologies (DMT),
Denmark, Netherlands). For some experiments, endothelium was denuded by passing a
fine metal wire through the vessel lumen. The vessel was immersed in 10 ml of D-PBS
and secured at both ends using two 11-O silk suture ties at each end. The myograph
chamber temperature was maintained at 37˚C and the vessel pressures maintained at
constant inlet (45 mmHg) and outlet (42 mmHg) pressures to achieve flow through the
vessel. The MMP-1 dose response was run in 10-fold increments in concentrations 0.02525 ng/ml in endothelium intact as well as endothelium denuded omental vessels. The
MMP-1 dose response was repeated with perfusion of 10 µM PAR-1 inhibitor SCH79797 (Tocris, Ellisville, Missouri) or 5 µM ET-1 Type A receptor blocker, BQ-123
(Sigma-Aldrich, St.Louis, Missouri). The Ang II dose response was run alone in 10-fold
increments (0.001-10 µM) and in the presence of 2.5 ng/ml of MMP-1. The Ang II dose
response in the presence of MMP-1 was repeated with perfusion of 10 µM SCH-79797 or
5 µM BQ-123.
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Data Analysis
The myograph experiment data were analyzed by one-way ANOVA and
Bonferroni post-test (MMP-1 dose response data) or two-way ANOVA with Bonferroni
posttests (Ang II dose response plus MMP-1 data) using a statistical software program
(Prism 4, GraphPad software, San Diego, CA). Data are presented as mean ± SE.

C. Results

MMP-1 dose response
As shown in Figure 25, when MMP-1 was perfused through the vessel lumen in
endothelium intact human omental vessels it caused dose dependent vasoconstriction
ranging from an average decrease of 5 µ with 0.025 ng/ml MMP-1 to an average decrease
of 40 µ with 25 ng/ml MMP-1. When MMP-1 was perfused through the vessel lumen in
endothelium denuded human omental vessels, it did not cause dose dependent
vasoconstriction.

Role of PAR-1 and ET-1 in MMP-1 induced vasoconstriction
As shown in Figure 26, co-perfusion of a PAR-1 inhibitor (10 µM SCH-79797)
with MMP-1 in endothelium intact omental vessels abolished MMP-1 induced
vasoconstriction. As shown in Figure 27, co-perfusion of 5 µM BQ-123, an ETA receptor
blocker, with MMP-1 in endothelium intact omental vessels also abolished MMP-1
induced vasoconstriction.
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MMP-1 mediated enhancement of vascular reactivity to Ang II
As shown in Figure 28, dose response to Ang II alone in endothelium intact
vessels ranged from a 4 µ mean decrease in vessel diameter with 0.001 µM Ang II and up
to a 16 µ mean decrease with 10 µM Ang II. When activated MMP-1 (2.5 ng/ml) was
perfused through the vessel lumen and the Ang II dose response was repeated, vascular
reactivity to Ang II at all doses (0.001 µM to 10 µM) was significantly enhanced. Vessel
diameter decreased by an average of 10 µ with 0.001 µM Ang II and an average of 43 µ
with 10 µM Ang II in the presence of MMP-1. Vasoconstriction to MMP-1 alone was
excluded to calculate the change in vessel diameter induced by the Ang II dose.

Role of PAR-1 and ET-1 in MMP-1 induced enhanced vascular reactivity to Angiotensin
II
Co-perfusion of a 10 µM SCH-79797, a specific PAR-1 inhibitor, with Ang II
plus MMP-1 abolished MMP-1 enhanced vascular reactivity to Ang II (Fig. 29).
Similarly, co-perfusion of 5µM BQ-123, an ETA receptor blocker, abolished enhanced
vascular reactivity to Ang II induced by MMP-1 (Fig.30).

D. Discussion
In this study we demonstrated for the first time that MMP-1 perfusion caused
dose-dependent vasoconstriction in endothelium intact human omental vessels and also
enhanced vascular reactivity to Ang II. Both of these effects were abolished by co-
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perfusion with a PAR-1 inhibitor or an ETA receptor blocker. These data indicate that
MMP-1 induced vasoconstriction and enhanced vascular reactivity to Ang II is mediated
by PAR-1 activation leading to release of ET-1 acting on the ETA receptor.
MMP-1 is best known as a collagenase. However, in recent years it has been
reported to activate the thrombin receptor, PAR-1, by cleaving the N-terminal peptide
sequence just two amino acids distal to the thrombin cleavage site209, 210, 212, 213. PAR-1 is
expressed on the surface of endothelial cells and its activation by either MMP-1 or
thrombin results in endothelial cell activation as evidenced by release of chymase, IL-8,
P-selectin and ET-1 from the Weibel Palade bodies within the endothelial cells18, 217, 232.
Thus, MMP-1 can mediate its vasoconstrictive effects by PAR-1 mediated release of ET1, a potent vasoconstrictor. PAR-1 activation also up-regulates expression of activated
MMP-2233, which is known to cleave big endothelin to ET-1234. ET-1 is a vasoconstrictor
and has been shown to enhance vascular reactivity to Ang II198 via activation of ETA
receptors on vascular smooth muscle cells235.
In normal pregnancy, basal levels of MMP-1 and ET-1 may have a role in
maintaining vascular tone198. However, in preeclampsia, levels of MMP-1 and ET-1236,8
are significantly greater than in normal pregnancy. Neutrophils can produce MMP-1218,
thus, activated neutrophils in the maternal circulation are a potential source of elevated
plasma levels of MMP-1 in preeclampsia. Another source of elevated plasma levels is
release of MMP-1 by vascular smooth muscle cells resulting from release of TNF-α by
infiltrating neutrophils237. Our recent findings of greater gene and protein expression of
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MMP-1 in omental and subcutaneous fat vessels in preeclamptic women support a role
for MMP-1 in the pathogenesis of preeclampsia.
In this study, we demonstrated that the presence of activated MMP-1 in the lumen
of resistance vessels caused dose dependent vasoconstriction and enhanced the
vasoconstrictive response to Ang II via PAR-1 activation and ET-1. In preeclamptic
women elevated levels of MMP-1 might explain enhanced vascular reactivity to Ang II.
MMP-1 induced narrowing of vessels, even at normal Ang II levels, would lead to
increased intravascular hydrostatic pressure and reduced capacity of the vascular system
resulting in high blood pressure and a tendency towards extravasation of intravascular
fluid leading to edema, features common to preeclampsia.

E. Perspectives
These data are the first to show that activated MMP-1 causes vasoconstriction and
enhances vascular reactivity to Ang II. These new data could provide novel avenues for
treatment of preeclampsia by targeting PAR-1 or ETA receptor. Potential treatments that
are available and being used clinically for other indications are the class of ETA/B
antagonists, like Bosentan, and SCH 530348, an orally active PAR-1 inhibitor238.
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Figure 25. MMP-1 induced vasoconstriction: Role of endothelium. MMP-1 perfusion into
the vessel lumen caused dose dependent vasoconstriction (0.25-25 ng/ml) in endothelium
intact human omental vessels (N=12). MMP-1 perfusion did not induce vasoconstriction
in the absence of endothelium (N=4). (*p<0.05, ** p<0.01, *** p<0.001)
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Figure 26. Role of protease activated receptor-1 (PAR-1) in MMP-1 induced
vasoconstriction. In endothelium intact human omental vessels, perfusion of 10 µM SCH79797, a specific PAR-1 blocker inhibited MMP-1 induced vasoconstriction (N=5, *
p<0.05, **p<0.01, *** p<0.001).
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Figure 27. Role of ET-1 in MMP-1 induced vasoconstriction. In endothelium intact
human omental vessels, perfusion of 5 µM BQ-123, a specific endothelin type-A (ETA)
receptor blocker, inhibited MMP-1 induced vasoconstriction (N=5, *p<0.05, ***
p<0.001).
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Figure 28. Vascular reactivity to Ang II in the presence of MMP-1 in endothelium intact
human omental vessels. Perfusion of MMP-1 (2.5 ng/ml) through the vessel lumen
significantly enhanced vascular reactivity to Ang II in endothelium intact human omental
vessels at all doses of Ang II tested. (N=12, *p<0.05, ** p<0.01, *** p<0.001).
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Figure 29. Effect of PAR-1 inhibitor on vascular reactivity to Ang II in the presence of
MMP-1 in endothelium intact human omental vessels. Perfusion of 10 µM SCH-79797, a
specific PAR-1 blocker, abolished MMP-1 mediated enhancement of vascular reactivity
to Ang II. (N=4, *p<0.05, ** p<0.01).
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Figure 30. Effect of ETA receptor blocker on vascular reactivity to Ang II in endothelium
intact human omental vessels. Perfusion of 5 µMBQ-123, a specific ETA receptor blocker
abolished MMP-1 mediated enhancement of vascular reactivity to Ang II. (N=4, *p<0.05,
** p<0.01).

Chapter 5

PHOSPHATIDYL INOSITOL 3-KINASE AND INSULIN RESISTANCE IN
PREECLAMPSIA

A. Introduction

Women with preeclampsia have increased incidence of insulin resistance and
show changes similar to that of metabolic syndrome. For example, Martinez et al
reported 73% higher fasting plasma insulin concentrations and four-fold higher post-load
plasma insulin levels in preeclamptic women239. Kaaja et al showed the presence of
hypertriglyceridemia, low HDL2 cholesterol and hyperuricemia in the blood of
preeclamptic women240.

Insulin Resistance

i.

Definition: Insulin resistance (IR) is the condition in which normal amounts of insulin
are inadequate to produce a normal insulin response from fat, muscle and liver cells
(en.wikipedia.org/wiki/Insulin_resistance).

Compensatory

increase

in

insulin

production by the pancreatic β-islet cells leads to hyperinsulinemia. Hyperinsulinemia
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protects against the rise in blood glucose levels until the compensatory ability of the
pancreas is overwhelmed and overt diabetes mellitus (DM Type II) is manifest. Thus,
insulin resistance is a prelude to diabetes and maybe present in the absence of glucose
intolerance.
Insulin resistance

ii.

Glucose Intolerance

DM Type II

Insulin Signaling Pathway:
Insulin rapidly stimulates glucose uptake by the muscle cells and adipocytes by

accelerating GLUT-4 translocation. GLUT-4 transporters mediate facilitated glucose
uptake into the cell. The rate-limiting step at which insulin stimulates glucose uptake is
translocation of GLUT-4 transporters to the plasma membrane241. GLUT-4 translocation
involves synthesis of specialized vesicles containing GLUT-4 transporters by the
endosomal system, transport of these vesicles from the perinuclear region towards the
plasma membrane, followed by fusion with the plasma membrane242.
Phosphatidyl inositol 3-kinase (PI3K) dependent Pathway (Fig.31): The insulin
receptor is a hetero-tetrameric membrane protein composed of two identical α and β
chains. Insulin docking at its binding site between the two α chains results in
autophosphorylation of the tyrosine residues within the β subunits. This recruits insulin
receptor substrates (IRS) which bind to the activated insulin receptor via phosphotyrosine
binding. This results in tyrosine phosphorylation of IRS by the activated insulin
receptor243. Tyrosine phosphorylation of insulin receptor substrates recruits the regulatory
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subunit p85 of PI3K and brings the catalytic subunit p110α close to the membrane. PI3K
p110α generates phosphatidyl inositol 3,4,5-triphosphate (PIP3) from phosphatidyl
inositol (4,5)-bisphosphate. The PIP3 then activates 3’ phosphoinositide-dependent
kinase-1 (PDK-1). Activation of PDK-1 leads to phosphorylation and activation of
protein kinase Akt (protein kinase B) and also protein kinase C λ/ς. Wortmannin and L294002, PI3K inhibitors, as well as biological blockade of PI3K signaling pathway using
dominant negative mutants inhibit insulin stimulated GLUT-4 translocation and glucose
uptake244-247. Phosphorylation of Akt substrate 160 (AS160) by protein kinase Akt
activates AS160. Activation of AS160 activates the GTPase activating domain (GAP)
for Rabs, which are small G-proteins important for vesicle formation, movement and
fusion248. The GTPase activating domain for a Rab on AS160 is essential for GLUT-4
translocation249.
Khan et al hypothesized the existence of an alternative PI3K independent pathway
for insulin mediated GLUT-4 translocation acting via changes in the cytoskeleton and
lipid raft organization250. The contribution of this pathway, if any, would be minimal and
the PI3K dependent pathway remains to date the most important pathway for insulin
mediated GLUT-4 translocation.

iii.

Evidence of Insulin Resistance in Preeclampsia:
Women with preeclampsia show hyperglycemic responses to both oral and

intravenous glucose load tests251, 252. Women with pregnancy-induced hypertension have
been shown to have higher fasting levels of insulin239,

240, 253

and increased insulin
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. The higher

239, 253

response to oral glucose load as compared to the normotensive women

insulin levels with similar glucose tolerance curves demonstrate development of insulin
resistance. Martinez et al showed that though the glucose tolerance curves did not differ
significantly, fasting plasma insulin concentrations were significantly higher and postload plasma insulin values fourfold higher in the preeclamptic group than normal
pregnant group239. Sowers et al showed that women who subsequently developed
preeclampsia had higher fasting plasma insulin levels at 20 weeks than control who
maintained normotensive values252.
Insulin resistance along with obesity characterize metabolic syndrome. One-third
of all preeclamptic pregnancies have metabolic syndrome254. Higher serum insulin levels
have been shown to persist for as long as 17 years after preeclamptic pregnancy255.
Development of preeclampsia may contribute to an increased risk of cardiovascular
diseases in later life256,
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. Obesity is a risk factor for preeclampsia and is also

characterized by inflammation of the vasculature, insulin resistance, hypertension,
hypertrigylceridemia, hyperlipidemia, low HDL2 and hyperuricemia240 forming a clinical
picture of metabolic syndrome in preeclampsia.

iv.

Preeclampsia and Insulin Resistance: The Common Link - Inflammation?
Inflammation of the systemic vasculature is a common feature of obesity and

preeclampsia. Walsh and colleagues have shown the presence of increased numbers of
activated neutrophils in the vasculature of normal weight preeclamptic women95, 96,
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and non-pregnant obese women97. The degree of inflammation correlates with the extent
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of obesity. This state of chronic inflammation is associated with oxidative stress and the
local release of cytokines like TNFα, which interferes with insulin signal transduction259,
260

and possibly GLUT-4 translocation.
Oxidative stress within neutrophils generates NO2+ (nitronium ion). NO2+ nitrates

protein tyrosine residues to 3-nitrotyrosine in a reaction catalyzed by superoxide
dismutase (SOD)261. Tyrosine nitration may have the potential to interfere with tyrosine
phosphorylation involved in insulin signaling thus contributing to insulin resistance in
preeclampsia.

v.

Role of TNF-α in development of insulin resistance:
Studies in knock out mice of TNF-α gene, as well as its two receptors, provided
direct evidence of TNF-α as an inhibitor of the insulin-signaling pathway262. In ob/ob
mice and dietary induced obese mice, ablation of TNFα improved insulin sensitivity and
prevented the obesity related insulin resistance in muscle and adipose tissue262.
Plomgaard et al demonstrated that TNFα infusion in healthy humans induced insulin
resistance without an effect on endogenous glucose production263. TNFα specifically
induces insulin resistance by increasing serine phosphorylation of insulin receptor
substrate-1 (IRS-1). This converts IRS-1 to an inhibitor of tyrosine kinase activity259, 264.
As discussed earlier, IRS-1 plays an important role in effecting insulin mediated GLUT-4
translocation and glucose uptake in skeletal muscle265. TNFα inhibits AS160
phosphorylation. Phosphorylation of AS160 promotes GLUT-4 exocytosis to the plasma
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249, 266

membrane facilitating glucose uptake

. Thus, TNFα inhibits GLUT-4 translocation,

and as a result, promotes insulin resistance.
Though there is no direct evidence showing down-regulation of PI3K in response
to TNFα, it is likely that TNFα down-regulates the activity and or expression of PI3K as
PI3K is the direct downstream target of tyrosine phosphorylated IRS-1 and upstream of
pAkt, both of which have been shown to be inhibited by TNFα263. In preeclamptic
women the levels of TNFα and its soluble receptors are significantly higher than those in
normal pregnant women267. TNFα is a major secretory product of purified
cytotrophoblast cells exposed to hypoxic conditions in vitro and in villous explants268.
Walsh and Wang reported increased TNFα levels and mRNA expression in preeclamptic
placentas69.
In 2005, Vaughan and Walsh showed that neutrophils from normal pregnant
women when activated by oxidative stress and linoleic acid released TNF-α
preeclampsia, there are elevated levels of linoleic acid,269
neutrophil infiltration within the systemic vasculature95,

96, 258
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. In

oxidative stress230 and
. Thus, local release of

TNFα by activated neutrophils270 infiltrating the systemic vasculature could mediate the
insulin resistance seen in preeclampsia. We hypothesized that activated neutrophils and
neutrophil products, like TNFα and ROS, will impair PI3K expression in vascular
smooth muscle cells thus contributing to insulin resistance in preeclampsia.

B. Materials and Methods
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Placental arterial smooth muscle (PASM) cells were grown in culture and treated
with control (medium M-199), neutrophils activated using arachidonic acid (50µM),
TNF-α (1 ng/ml) or ROS generating solution in medium M-199, described in detail in
Chapter 2. To quantify PI3K p85α and p110α by Western blot, PASM cells were grown
and treated with cell treatments in T-25 flasks overnight. The media was aspirated
followed by scraping the cells in 1 ml of ice cold sterile PBS. The cells scraped in PBS
were centrifuged at 2000 x g at 4˚C for 5 minutes. After discarding the supernatant, 200
µl of M-PER buffer was added and mixed well. The cell suspension with M-PER buffer
was placed on a shaker for 10 min and then centrifuged at 14,000 x g for 20 minutes. The
supernatant was collected and frozen to -80˚C. The pellet of cell debris was discarded.
Protein concentration in the collected supernatant was quantified using the Pierce BCA
Protein Assay Kit.
To prepare 2 ml of M-PER buffer, 80 µl of protease inhibitor (PI) stock solution
and 40 µl of 100 mM sodium orthovanadate (SOV) was added to 1.880 ml of M-PER
(Pierce). PI stock solution was prepared by dissolving 2 Complete PI tablets (Roche) in 4
ml of ddH2O and stored as 150 µl aliquots at -20˚C for up to 12 wks. Solution of SOV
was prepared as 10 ml of 100 mM SOV in ddH2O in a 50 ml polypropylene tube. The pH
was adjusted to 10.0 using 1 N hydrochloric acid (HCl) and warmed in a beaker of
boiling water till the solution turned clear (approx 20 minutes). After the solution had
cooled to room temperature, it was stored in 100 µl aliquots at -20˚C. For Western
blotting, the Invitrogen Xcell Surelock system was used for electrophoresis and the
Odyssey (Licor) system was used for scanning fluorescence tagged secondary antibodies.
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Sample Preparation: Equal concentrations of protein per sample were calculated
and volumized to 22.5 µl with ddH2O. To this 1.5 µl of 20X reducing agent and 6 µl of
5X Laemli’s Buffer were added. Samples were placed in boiling water at 100˚C for 15
minutes followed by cooling on ice and centrifugation at 4˚C for 1 minute. The samples
were then applied to the wells of the gel using gel loading pipette tips. Biorad All Blue
protein standards were run in the first lane of every Western blot.
Antibodies, Electrophoresis and Transfer for PI3K p85α, p110α: Primary rabbit
monoclonal anti-PI3K p110α antibody (Cell signaling technologies, 1:500) and anti-PI3K
p85α antibody (Millipore, 1:1000) were used for overnight incubation at 4˚C. Primary
mouse monoclonal anti-β actin Ig (Sigma, 1:10,000) was added to control for variable
protein loading. Secondary antibodies, IRDye 800 anti-mouse antibody (Licor, 1:30,000)
and AlexaFluor 680 goat anti-rabbit antibody (Invitrogen, 1:10,000) were incubated for
45 minutes at room temperature. When stored at 4˚C, both primary and secondary
antibody solutions could be re-used several times.
For electrophoresis, precast 8% Novex Tris-Glycine mini-gels from Invitrogen
were used with sample loading of 25 µg protein/well and electrophoresis was run at 125V
for 1.5 hours. After electrophoresis, the gel was washed with ddH2O followed by
equilibration in methanol free transfer buffer for 15-20 minutes. A 0.45 µ pore size PVDF
membrane (Millipore) was wetted in 100% methanol for 30 seconds followed by rinsing
in ddH2O and equilibration in methanol free transfer buffer for 15 minutes. Ice cold
methanol free transfer buffer was used to soak the blotting pads taking care to remove all
air bubbles. The sandwich for transfer composed of 3 blotting pads, filter paper, gel,
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PVDF membrane, filter paper and 3 blotting pads was assembled and transfer was run for
3 hours at 35V. Coomasie blue staining of the gel was used to confirm optimal transfer of
protein.
Quantification of PI3K was done using densitometric analysis by Odyssey
software. The values were normalized to β-actin and calculated as a percentage of control
to be compared by one-way ANOVA and the Newman Keuls post-test.

C. Results

i. PI3K p85α Western Blot
As shown in Fig. 32, expression of the regulatory sub-unit of phosphatidyl inositol 3kinase, p85α, in primary human vascular smooth muscle cell culture was significantly
decreased when co-cultured with activated neutrophils overnight (N=4, p<0.05).
Similarly neutrophil products like ROS (N = 6, * p<0.05) and TNFα (N = 7, ** p<0.01)
also significantly decreased expression of PI3K p85α.

ii. PI3K p110α Western Blot
As shown in Fig. 33, expression of the catalytic sub-unit of phosphatidyl inositol 3kinase, p110α, in primary human vascular smooth muscle cell culture was significantly
decreased when co-cultured with activated neutrophils overnight (N=4, p<0.05).
Similarly neutrophil products like ROS (N = 5, * p<0.05) and TNFα (N = 6, ** p<0.01)
also significantly decreased expression of PI3K p110α.
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D. Discussion
Our data show that activated neutrophils and the neutrophil products, ROS and
TNF-α, significantly decrease expression of the PI3K regulatory and catalytic subunits,
p85α and p110α, respectively, in primary human vascular smooth muscle cell culture.
The catalytic subunit of PI3K, p110α, is important for GLUT-4 mediated glucose uptake
(Fig. 31). It is interesting to note that TNF-α inhibits insulin signaling and glucose
metabolism in humans271,

272

but not in rodents273. This brings to light inter-species

differences in the sensitivity to cytokines, which may be one of the reasons preeclampsia
is a disorder unique to human pregnancy.
TNF-α is known to affect intracellular insulin signaling in fat, skeletal muscle
and other insulin responsive tissues by inhibiting kinase activity in the proximal part of
the insulin-signaling pathway260, 274, 275. TNF-α also affects a similar signaling pathway in
vascular endothelium that results in production of nitric oxide (NO)276, which mediates
insulin-stimulated vasodilation277-279. We show that neutrophils and ROS also affect
insulin-signaling pathway by decreasing the regulatory (p85α) and catalytic (p110α)
subunits of PI3K. Thus, in addition to TNF-α, neutrophils and ROS also contribute to
insulin resistance and vascular dysfunction in preeclampsia.
Neutrophils could be involved in maintaining a vicious cycle perpetuating insulin
resistance by down-regulation of PI3K. TNFα release by activated neutrophils in the
maternal circulation or within the vasculature would inhibit the PI3K/Akt pathway.
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Inhibition of the PI3K/Akt pathway within the vascular smooth muscle cells would
inhibit GLUT-4 translocation and thus induce insulin resistance259, 263, 264, 272.
Although hypertension of preeclampsia falls rapidly with delivery of the placenta,
Fuh et al reported that it took 2 months after delivery for the insulin insensitivity to
decrease280. Jacober et al reported no difference in insulin sensitivity 3-6 months postpartum281. With delivery of the placenta, a major source of lipid peroxides is lost,
reducing oxidative stress. Without the placenta, there is no ongoing neutrophil activation
and TNFα release. Eventually, new neutrophils are released from the bone marrow and
the state of vascular inflammation can be reversed. Thus, neutrophil infiltration and
release of TNFα could explain the reversible nature of the insulin resistance seen in
preeclamptic women.
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Figure 31. Phosphatidyl inositol 3-kinase (PI3K) dependent insulin mediated GLUT-4
translocation pathway. Insulin mediated activation of insulin receptor causes tyrosine
phosphorylation of insulin receptor substrate-1 (IRS-1) which activates the regulatory
(p85α) and catalytic subunits (p110α) of PI3K. Activated PI3K phosphorylates its
substrate, membrane phosphatidyl inositol 3,4,5 triphosphate, to result in phosphorylation
of Akt and Akt substrate 160 (AS160). Activation of AS160 activates the GTPase
activating domain (GAP) for Rabs, which are small G-proteins important for vesicle
formation, movement and fusion248. The GTPase activating domain for Rab on AS160 is
essential for GLUT-4 translocation. When in the plasma membrane, GLUT-4 receptors
facilitate glucose uptake by the cells.
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Figure 32. Expression of the regulatory sub-unit of phosphatidyl inositol 3-kinase, p85α,
in vascular smooth muscle cell culture. Expression of p85α is significantly decreased
with treatments of activated neutrophils (N=4, * p<0.05) or neutrophil products, ROS
(N=6) and TNFα (N = 7,** p<0.01).
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Figure 33. Expression of the catalytic sub-unit of phosphatidyl inositol 3-kinase, p110α,
in vascular smooth muscle cell culture. Expression of p110α is significantly decreased
with treatments of activated neutrophils (N=4, * p<0.05) or neutrophil products, ROS
(N=5,* p<0.05) and TNFα (N = 6, ** p<0.01).

CHAPTER 6
DISCUSSION
This investigation is the first to demonstrate a cause for the development of
hypertension in preeclampsia. It goes on to explain the pathways by which neutrophils
and neutrophil products can give rise to the pathogenesis of preeclampsia. We began by
noting the significantly increased neutrophil infiltration and inflammation within the
systemic vasculature of preeclamptic women96 and proposed that this neutrophil
infiltration leads to increased vessel reactivity to Ang II, which is seen in women
predestined to develop preeclampsia123.
We began our investigation by testing vessel reactivity to Ang II in omental
vessels from normal pregnant women with perfusion of activated neutrophils through the
vessel lumen. The presence of neutrophils significantly increased vessel reactivity to Ang
II. Increased vessel reactivity to Ang II leads to hypertension and reduced circulatory
volume in preeclampsia.
Activated neutrophils release a number of inflammatory mediators, such as ROS
and TNF-α. To elucidate the mechanism by which neutrophils increase vessel reactivity
to Ang II, we tested vessel reactivity to Ang II with perfusion of neutrophils in the
presence of SOD/catalase to quench the ROS generated. This abolished the increased
vessel reactivity observed with neutrophils. To confirm the role of ROS, and to exclude
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the role of other neutrophil products like TNF-α, we repeated the Ang II dose response in
the presence of a ROS generating solution and also with TNF-α. While ROS enhanced
vessel reactivity to Ang II similar to that seen with neutrophil perfusion, TNF-α did not
affect vessel reactivity to Ang II.
A major mechanism of increasing vessel reactivity to Ang II in vascular smooth
muscle cells is the RhoA kinase pathway. ROS can activate RhoA kinase134. Therefore, to
determine whether ROS were activating RhoA kinase to result in enhanced vessel
reactivity, we used Y-27632, a specific RhoA kinase inhibitor. Addition of Y-27632
significantly reduced the increased vessel reactivity to Ang II in the presence of
neutrophils or ROS. To confirm the role of the RhoA kinase pathway, we measured
RhoA kinase activity using a previously validated assay in omental vessels treated with
ROS224. Omental vessels exposed to ROS showed a 3-fold increase in RhoA kinase
activity as compared to control vessel segments.
We also quantified expression levels of Thr-696 pMYPT1 and Ser-19 pMLC in
vascular smooth muscle cell culture treated with Ang II plus ROS or neutrophils, with
and without Y-27632. Both ROS and neutrophils significantly increased expression
levels of pMYPT1 and pMLC in the absence of Y-27632, but not in the presence of Y27632. Thus, we conclude that neutrophil release of ROS activates RhoA kinase to
increase vessel reactivity to Ang II.
To determine if ROS activation of RhoA kinase could affect vessel reactivity to
other vasoconstrictors, we tested NE in the presence of ROS, with or without Y-27632.
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We found that ROS activation of RhoA kinase also enhanced vessel reactivity to NE, so
ROS enhancement of vessel reactivity appears to be a generalized mechanism.
In light of the recent findings of increased expression of MMP-1 within the
systemic vasculature of preeclamptic women with increased MMP-1 gene expression in
omental vessels and increased plasma levels of MMP-1 in preeclamptic women (EstradaGutierrez, unpublished), we proposed a role of MMP-1 in the pathogenesis of
preeclampsia. We found that MMP-1 caused direct dose-dependent vasoconstriction and
enhanced vessel reactivity to Ang II in endothelium intact vessels. Both effects were
mediated via PAR-1 endothelial activation and release of ET-1.
Women with preeclampsia also have insulin resistance240. To determine whether
neutrophils or neutrophil products could play a role in the development of insulin
resistance, we quantified protein expression levels of the regulatory (p85α) and catalytic
(p110α) subunits of PI3K in vascular smooth muscle cell culture with treatments of
activated neutrophils, ROS, TNF-α and control. Neutrophils, ROS and TNF-α
significantly decreased expression of the catalytic subunit (p110α) of PI3K. Neutrophils
and TNF-α also significantly decreased expression of the regulatory subunit (p85α) of
PI3K. PI3K plays a pivotal role in insulin-mediated GLUT-4 translocation to the plasma
membrane244, 247, so a neutrophil mediated decrease in PI3K would interfere with cellular
glucose uptake. Decreased glucose uptake by cells is a hallmark of insulin resistance.
Our results demonstrate that neutrophils and neutrophil products act as the
common denominator in the pathogenesis of preeclampsia contributing to increased
vessel reactivity and vasoconstriction leading to hypertension along with insulin
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resistance forming a clinical picture of preeclampsia (Fig.35). Our recent finding of
extensive vascular infiltration of neutrophils in women with preeclampsia95, 96 challenged
conventional thinking because neutrophils are usually thought of as part of the innate
immune system and the first line of defense against infection at the site of a wound53
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.

A role for neutrophils in a non-infectious disease, like preeclampsia, has not been widely
studied. However, accumulating evidence indicates a role for neutrophils in “sterile”
inflammatory diseases227. The reason neutrophils may be playing an important role in
pregnancy is that in normal pregnancy, the number of neutrophils increases 2.5-fold by
30 weeks of gestation
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and this number increases further in preeclampsia
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. The

human placenta produces oxidized lipids and secretes them into the maternal circulation
36, 38, 69, 159, 229

. Oxidized lipids are potent activators of neutrophils 66, 68, 191. In women with

preeclampsia, placental production of oxidized lipids is significantly higher than in
women with normal pregnancy38. One possibility for neutrophil activation occurs as they
circulate through the intervillous space and are directly exposed to oxidized lipids
released by the placenta36,

230, 231

.

Activated neutrophils in the maternal systemic

circulation adhere to the endothelium and could cause vascular inflammation and
dysfunction

by

release

of

toxic

compounds.

Neutrophil

release

of

matrix

metalloproteinase-8 and myeloperoxidase could compromise vascular integrity.

Neutrophils also express and produce MMP-1218. Moreover, our lab has shown
that neutrophil and neutrophil products stimulate VSMC to produce MMP-1 and IL-8
(Estrada-Gutierrez, Walsh, unpublished). IL-8 being a chemo attractant to neutrophils
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will attract more neutrophils into the vasculature forming a self-perpetuating cycle of ongoing neutrophil infiltration leading to increasing production of MMP-1 contributing to
increasing vasoconstriction and worsening of hypertension. Constant production of
MMP-1 by VSMC under the influence of neutrophils could be another mechanism to
explain the increased vessel reactivity to Ang II. The vascular effects of MMP-1 were
mediated via PAR-1. PAR-1 expression is significantly increased in preeclamptic
omental vessels as compared to normal pregnant women; and in VSMC neutrophils, ROS
and TNF-α significantly increase PAR-1 expression (Estrada-Gutierrez, Walsh,
unpublished). Thus, the effects of MMP-1 would likely be magnified many fold in
preeclamptic women with both endothelial and VSMC expressing PAR-1. One of the
limitations of the present study is that vessels from preeclamptic women were not
evaluated. It would be interesting to repeat these experiments in vessels from
preeclamptic women and evaluate the role of PAR-1 mediated direct intracellular calcium
entry into VSMC as future studies. Also, MMP-1 is a collagenase, like MMP-8
(neutrophil collagenase), and could compromise vascular integrity which when coupled
with increased hydrostatic pressure as a result of enhanced vascular reactivity to Ang II,
would lead to extravasation of protein. Thus, neutrophil infiltration and increased MMP-1
may be contributing not only to hypertension, but also to the edema and proteinuria seen
in preeclampsia.
Apart from vasoconstriction and increased vascular reactivity leading to
hypertension in preeclampsia, neutrophils and neutrophil products also inhibited VSMC
expression of regulatory and catalytic subunits of PI3K which could explain insulin
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resistance in preeclampsia. These studies were done in VSMC culture and future studies
for PI3K activity in preeclamptic vessels compared to normal are warranted. Moreover, it
would be interesting to do real time polymerase chain reaction for quantifying gene
expression along with epigenetic studies to determine if neutrophils or neutrophil
products lead to epigenetic alteration of the PI3K genes.
In conclusion, neutrophils may be playing a key central role in the pathogenesis of
preeclampsia (Fig. 34). Neutrophil products like ROS and MMP-1 can increase vessel
reactivity to cause hypertension, while ROS and TNF-α inhibit PI3K to cause insulin
resistance. Moreover, MMP-1 can also cause direct vasoconstriction and compromise
vascular integrity that could lead to edema and proteinuria.
The work presented in this thesis offers several options for development of
preventive and therapeutic treatments for preeclampsia. For example, use of neutrophil
neutralizing antibodies and antibodies against adhesion molecules could prevent
neutrophil infiltration of the systemic vasculature and thus prevent development of
clinical manifestations of preeclampsia, or even reverse signs of preeclampsia by
preventing new neutrophil infiltration. RhoA kinase inhibitors could be studied to
determine their ability to control blood pressure in preeclampsia by blocking
enhancement of vessel reactivity to Ang II and NE. MMP-1 neutralizing antibodies could
possibly impair the ability of MMP-1 to induce vasoconstriction, enhance vessel
reactivity and compromise vascular integrity, thus potentially reducing blood pressure
and reversing edema and proteinuria. Since the vasoconstrictive properties of MMP-1 are
mediated via PAR-1 and ET-1 release, PAR-1 inhibitors and ETA receptor blockers
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would be excellent drug development targets to pursue for blood pressure control in
preeclampsia. Intracellular pharmacologic stimulators of PI3K could be developed and
studied as potential drugs to regain insulin sensitivity. This could also find application in
the treatment of obesity associated metabolic syndrome and Type II DM, in addition to
the treatment of preeclampsia. Thus, the work presented in this thesis has multiple
applications and serves to better understand the complex pathogenesis of preeclampsia, a
leading cause of maternal and neonatal mortality and morbidity.

117

PREECLAMPSIA
Vasoconstriction

Increased
vessel
reactivity

Insulin Resistance

MMP-1
TNF-α
Reactive Oxygen Species

Vascular Infiltration
of Neutrophils

Common Denominator
Figure 34. Neutrophils: The common denominator in the pathogenesis of preeclampsia.
Vascular infiltration of neutrophils leads to production of reactive oxygen species that
lead to increased vessel reactivity and insulin resistance. Neutrophil release of MMP-1 or
stimulation of vascular MMP-1 leads to vasoconstriction, increased vessel reactivity and
compromised vascular integrity leading to hypertension, edema and proteinuria. On the
other hand, TNF-α, another neutrophil product, contributes to insulin resistance without
affecting vessel reactivity. Thus, vascular infiltration of neutrophils could explain the
development of hypertension, insulin resistance, edema and proteinuria in preeclampsia.
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